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ABSTRACT 
The main goal of this work was to characterize and explore the potential of 
Dioctadecyldimethylammonium Chloride (DODAC) / Monoolein (MO) liposomes in a 1:2 
proportion and identify the formulations that could be used in the development of an 
immunoprotective protocol for Chronic Myeloid Leukemia (CML). 
CML has long been recognized as one of the most responsive leukemic disorder to 
immunotherapy. CML is potent model for immune therapy in humans because there is a 
specific gene rearrangement, BCR/ABL, which product, P210bcr/abl, can be the target 
antigen. 
The loading of drugs into particles at the nanometer size range is a recognized technique for 
the optimization of controlled drug delivery. In its use in vaccines, liposomes have the 
advantage of being able to maintain antigens present in the organism for long enough to 
obtain an immune response. 
Different methods of preparation and distinct peptide/lipid molar ratios were used to prepare 
P210bcr/abl / DODAC:MO (1:2) nanoparticles. This thesis describes results for biophysical 
characterization of the peptide/lipid system, encapsulation efficiency and exposure of THP-1 
cells to the nanoparticles. 
The lipid content was essential to achieve the desired nanoparticles. The highest lipid 
concentration showed higher encapsulation, however, a lower lipid content induced a more 
efficient cell response. The peptide/lipid system was capable of inducing a stronger cell 
response than the peptide by itself, emphasizing the potential of this system in vaccine 
development for the treatment of CML. 
 
 
 
 
Key words: DODAC/MO (1:2), Chronic Myeloid Leukemia, BCR-ABL, vaccines.   
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RESUMO 
O objetivo principal deste trabalho foi caracterizar e explorar o potencial dos lipossomas de 
cloreto de Dioctadecildimetilamónio (DODAC) / Monooleina (MO) numa proporção de 1:2 e 
identificar as formulações que poderão ser usadas no desenvolvimento de um tratamento 
imunoprotetor para a Leucemia Mieloide Crónica (LMC).  
A LMC é desde há muito tempo conhecida como uma das desordens imunológicas mais 
responsivas à imunoterapia. A LMC é um poderoso modelo para imunoterapia em humanos 
devido à existência de um gene específico BCR/ABL, cujo produto, P210bcr/abl, pode ser 
usado como antigene-alvo. 
A incorporação de fármacos em partículas a uma escala nanométrica é uma técnica 
reconhecida para a optimização da entrega controlada de fármacos. No seu uso em vacinas, os 
lipossomas possuem a vantagem de ser capazes de manter os antigenes presentes no 
organismo o tempo suficiente para se obter uma resposta imune. 
Diferentes métodos de preparação e várias razões molares de péptido/lipido foram usadas para 
preparar nanoparticulas de P210bcr/abl / DODAC:MO(1:2). Esta tese descreve os resultados 
obtidos da caracterização biofísica do sistema péptido/lípido, eficiência de encapsulação e 
exposição das células THP-1 às nanopartículas. 
O conteúdo lipídico foi essencial para obter nanopartículas desejáveis. A concentração mais 
alta de lípido demonstrou maior eficiência de encapsulação, no entanto, uma concentração de 
lipído mais baixa mostrou-se mais eficiente em induzir uma resposta por parte das células. O 
sistema péptido/lipido foi capaz de induzir uma resposta mais forte do que o pétido por si só, 
enfatizando o seu potencial no desenvolvimento de uma vacina para o tratamento da LMC. 
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1. CHAPTER 1  BACKGROUND 
Nowadays, knowledge about the properties of nanoparticles and how to handle them is still 
limited, opening a wide field of work and scientific research in nanotechnology to be 
explored. New technology related to the treatment of cancer has become a major focus in the 
world and new systems that could not have been developed before are now being 
accomplished. Nanobiotechnology permits bringing together, targeting, therapeutic and 
imaging compounds condensed in single liposome-based delivery systems. Liposomes 
provide several benefits, and therefore, are ideal candidates for controlled drug release in the 
affected region. 
 
1.1. Goals 
The use of liposomes as carriers of biomolecules has been widely reported in the international 
literature as an important step in the production of vaccines or drug-delivery systems. The 
main goal of this work is to characterize and explore the potential of the system DODAC/MO 
(1:2) for peptide delivery, enhancing the imunopotentiating action of a CML specific peptide. 
This increased antigen immunization will activate tumor-specific T cells and consequently 
increase the therapeutic action of the molecule.  
For this purpose distinct approaches have been used throughout this work in order to fulfill 
three main stages: (i) inclusion of junctional peptide p210 from CML-specific oncoprotein 
BCR-ABL into liposomes (ii) encapsulation efficiency (iii) delivery of antigenic BCR-ABL 
junctional peptide to cells in vitro. 
 
1.2. Research motivation and contribution 
With the new nanotechnology instruments developed in the latest years and understanding the 
pathology involved, it is absolutely possible to develop an innovative strategy that could be 
extrapolated to other treatments. Indeed, considering the possibility of building combined 
systems with nano-sized particles and bioactive molecules, conditions are gathered to develop 
new vaccines with important therapeutic action. Furthermore, the interaction between 
Chapter 1  Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML 
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DODAC and MO is still poorly investigated, in spite of the potential application of such 
DODAC/MO mixture, which has also motivated the present investigation. 
Moreover, the possibility of benefiting from the interaction between the Centers of Physics 
and Environmental Biology from University of Minho, as well as with the BioPhotonics 
Group from the International Iberian Nanotechnology Laboratory (INL), makes this project a 
gratifying multidisciplinary experience. 
 
1.3. Dissertation organization 
This dissertation encompasses all the stages of the experimental work, beginning with the 
finding of the most suitable formulation of lipid/peptide in order to test its capability on 
triggering immunological responses. The work has been organized into five main chapters. 
Chapter 1 describes the main goals of this work. It also explains the research motivation and 
contribution as well as the dissertation organization. 
Chapter 2 provides a general overview on key factors related to physicochemical and 
biological parameters of liposome-based delivery systems for drug delivery and vaccine 
development. Detailed information about liposomes preparation is also presented. Moreover, 
principles and current status concerning treatment options for CML are discussed. 
Chapter 3 presents a detailed description of the methodology used to create an innovative 
system to treat CML patients. 
Chapter 4 presents data analysis that characterizes the peptide incorporation into the nano-
delivery system. Furthermore, data analysis regarding the system’s ability to induce an 
immune response is also discussed. 
In Chapter 5 conclusions and future directions are presented. 
Bibliography referenced in the text is listed at the end of the work. 
 
 
  
Chapter 2  
State of the art 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"There are known knowns. There are things we know we know. We also know there are 
known unknowns. That is to say we know there are some things we do not know. There are 
also unknown unknowns, the ones we don't know we don't know." 
Donald Rumsfeld (2002) 
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2. CHAPTER 2  STATE OF THE ART 
 
2.1. Liposomes  
Liposomes are nano-sized artificial vesicles of spherical shape in which an aqueous volume is 
entirely enclosed by a membrane composed of lipid molecules, usually phospholipids 
(Vemuri & Rhodes, 1995). These structural units are amphipathic molecules that have a polar 
or hydrophilic head group (has affinity for water molecules) and a nonpolar hydrophobic tail 
consisting of fatty acid chains (that repeals water molecules), as shown in Figure 2.1. 
Phospholipids are characterized by its solubility in organic solvents and low solubility in 
water. 
 
Figure 2.1 – Representation of the steric organization of a liposome (up) and lipid bilayer 
(bottom) (adapted from (Bitounis, Fanciullino, Iliadis, & Ciccolini, 2012)). 
 
Chapter 2  Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML 
6 Fátima Machado 
Liposomes were first introduced in the 60’s when Alec Bangham observed that phospholipids 
in aqueous solutions could form closed bilayer structures (Bangham, Standish, & Watkins, 
1965). In fact, when phospholipids are combined with water they immediately form a bi-
layered sphere, a process commonly referred as “self-assembly” by which a disordered system 
forms an organized structure due to the local interactions between the system units 
(monomers). Thus, they can be prepared so that they entrap materials both within their 
aqueous compartment and/or within the membrane. 
A model referred to as “fluidic mosaic” introduced in 1972 by Singer and Nicholson, 
proposes that biological membranes are composed of lipids, proteins and carbohydrates 
(Singer & Nicolson, 1972). Their biological structure is very similar to that of normal human 
cellular membranes. Therefore, liposomes are good study models for biological membranes. 
The properties and structure of the lipid bilayer can be affected by the gel or fluid state 
(Ryhänen, 2006). With increasing temperature, lipid vesicles constituted by one type of 
phospholipid goes through a transition from a gel state into a fluid “liquid crystalline” state. 
Each lipid has its own transition temperature (Tm) point, above which, in liquid crystalline 
state, lipid bilayer becomes more fluid and elastic with increasing diffusion of the individual 
lipid molecules (Ryhänen, 2006). The fluid state of lipids facilitates liposome production and 
manipulation. 
 
2.1.1. Particle Size 
Particle size affects drug release. Smaller particles have larger surface area, therefore, most of 
the drug associated would be at or near the particle surface, leading to fast drug release. 
However, smaller particles also have higher risk of aggregation. On the other hand, larger 
particles have larger cores which allow higher quantity of drug to be encapsulated and slowly 
diffuse out. The ability to produce nanoparticles of desired size with great precision (narrow 
size distribution and small variation) is the key factor of producing the nano-suspensions 
(Silva, Little, Ferreira, & Cavaco-Paulo, 2008). 
Liposomes are classified on the basis of different structural parameters and they are produced 
according to the purpose for which they are more suitable. Figure 2.2 presents different types 
of liposomes according to size and lamellarity. Multi-lamellar vesicles (MLV) are particles 
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that are usually up to 0,5 µm. The liposomes containing encapsulated vesicles are called 
multi-vesicular vesicles (MVV) and their size is up to 1 µm. Uni-lamellar vesicles ranging 
from 20-100 nm are referred to as SUV, whereas LUV are uni-lamellar vesicles bigger than 
100 nm. There are also liposomes of very large size that are called giant liposomes (>1µm) 
which can be either uni-lamellar or multi-lamellar. OLV are oligo-lamellar vesicles ranging 
from 100-500 nm. 
 
Figure 2.2 – Liposomes classification based on size and lamellarity (Laouini et al., 2012). 
 
2.1.2. Liposome preparation 
Different methods of liposome preparation allow the production of lipid vesicles with distinct 
structural parameters (Dua et al., 2012), as Figure 2.3 illustrates. 
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Figure 2.3 – Different types of liposomes produced by ethanol injection, lipid film hydration 
and extrusion: Small Uni-lamellar Vesicles (SUV); Large Uni-lamellar Vesicles (LUV); 
Multi-vesicular Vesicles (MVV); Multi-lamellar Vesicles (MLV) (courtesy from João Neves). 
 
Liposomes self-close to form large, multi-lamellar vesicles (MLV) which prevents interaction 
of water with the hydrocarbon core of the bilayer. Once these particles have formed, reducing 
the size of the particle requires the use of mechanical treatments such as extrusion through 
polycarbonate membranes that can transform the MLV suspension into LUV or SUV. 
Sonication is another alternative to reduce liposome size and produces SUV, and it can be 
applied to the other methods of preparation. 
Methods to prepare liposomes used in this work will be described in the following 
paragraphs. For further information, there are several reviewed methods (Dua et al., 2012; 
Laouini et al., 2012; Ulrich, 2002). 
 
A) Multi-lamellar Liposomes (MLV) 
Lipid hydration method 
First the lipids are thoroughly mixed in the organic solvent. After drying the lipid a thin film 
is formed at the bottom of round bottom flask. A suspension of MLV is readily obtained by 
hydrating the thin film with aqueous buffer dispersion.  For larger volumes, the organic 
solvent should be removed by rotary evaporation. After adding aqueous buffer, the solution 
should be under agitation for some time above the lipid phase transition temperature Tm of the 
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lipid or above the Tm of the highest melting component in the lipid mixture. The compounds 
to be encapsulated are added either to aqueous buffer or to organic solvent containing lipids 
depending upon their solubility. Spinning the round bottom flask in the warm water bath 
maintained at a temperature above the Tm of the lipid suspension allows the lipid to hydrate in 
its fluid phase. 
This is the most widely used method for the preparation of MLV (Figure 2.4), making it 
simple to prepare and a variety of substances can be encapsulated in these liposomes. As for a 
disadvantage of this method, the resulting size distribution and lamellarity of the MLV is very 
heterogeneous. Still, sophisticated procedures have been developed to produce uniformly 
sized liposomes (Frézard, 1999; Lasic, 1997; New, 1994). 
Alternatively, for small volumes of organic solvent (<1mL), the solvent may be evaporated 
using a nitrogen gas or argon stream over the mixture in a fume hood. After the removal of 
organic solvent an aqueous solution is added to hydrate and MLV are formed immediately in 
this aqueous phase. The content is then emulsified by vigorous vortexing and/or sonication. 
 
Figure 2.4 – Representation of MLV preparation by lipid hydration method (adapted from 
Lopes et al., 2013). 
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B) Multi-vesicular Liposomes (MVV) 
Ethanol injection method 
Another approach relies on injecting, drop by drop, the lipid dissolved in the organic solvent 
to a vast excess of buffer pre-heated to the Tm of the lipids, under vigorous vortexing. A 
heterogeneous mixture of SUV, LUV or MLV is immediately formed. Therefore, one of the 
drawbacks of the method is that the population is heterogeneous.  Furthermore, liposomes are 
very diluted, it is difficult to remove all ethanol because it forms an azeotrop with water, and 
various biologically active macromolecules may be inactivated in the presence of even low 
amounts of ethanol (Batzri & Korn, 1973). 
 
C) Large Uni-lamellar Liposomes (LUV) and Small Uni-lamellar Liposomes (SUV)  
(i) Sonication method  
Disruption of MLV suspensions (produced by lipid film hydration method) using ultra-sonic 
energy (sonication) typically produces SUV. The most widely used instrumentation for 
preparation of SUV is a bath sonicator. Sonication of MLV dispersion is accomplished by 
placing a test tube containing the suspension in a bath sonicator for a certain amount of time. 
Sonication can be applied to the other methods to increase efficiency in the formation of 
hydrated lipid vesicles of the smallest size. 
Mean size and its distribution are influenced by temperature, sonication time and power, 
volume, composition and concentration, and sonicator tuning. Thus, it is understandable that 
it is nearly impossible to reproduce the conditions of sonication, meaning that size variation 
between samples produced at different times is common. Moreover, due to the high degree of 
curvature of these membranes, SUV are unstable and have a tendency to undergo aggregation 
and fusion, forming larger vesicles when stored below their phase transition temperature. 
 (ii) Extrusion method 
This process, showed in Figure 2.5 consists in submitting a suspension of liposomes through a 
small orifice, repeatedly and sequentially, through polycarbonate membranes filter of well-
defined pore-size, under conditions of elevated pressure and temperature above the transition 
temperature of the lipid. LUV with a diameter near the pore size of the filter used, are 
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produced. Attempts to extrude below the Tm will be unsuccessful as the rigid membranes 
cannot pass through the pores. Interestingly, extruded vesicles have been reported to retain 
significantly elongated elliptical shapes, which have to be taken in to account when evaluating 
their size and entrapped volume (Jin, Huster, Gawrisch, & Nossal, 1999). The method has 
some advantages over sonication method, being simple and rapid, reproducible and involving 
gentle handling of unstable materials. The resulting vesicles are somewhat larger than 
sonicated SUV. 
 
 
Figure 2.5 – Representation of the extrusion process (Zhua, Xueb, Guob, & Marchant, 2007). 
  
2.1.3. Liposome-based delivery systems 
Soon after Alec Bangham observed that phospholipids in aqueous solutions could form closed 
bilayer structures (Bangham, Standish, & Watkins, 1965), the capture of liposomes by 
macrophages was recognized as the main mechanism by which liposomes potentiate immune 
responses to entrapped antigens, which was followed by many immunization studies (Alving, 
1991; Gregory Gregoriadis, 1990; Kersten & Crommelin, 1995; V. Torchilin, 2003). 
Liposomes were first proposed as drug delivery system more than 30 years ago (Gregoriadis, 
1973). 
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Since then, they have been extensively investigated for their potential as drug carriers. 
Advances in our understanding of the behavior of liposomes at the cellular and subcellular 
level have allowed the construction of bionanodevices for use in the treatment and prevention 
of a number of diseases. 
Allison and Gregoriadis (Allison & Gregoriadis, 1974), conducted a pioneer work that 
demonstrated the immunoadjuvant properties of liposomes. In the early 80s, the involvement 
and investment of several companies, parallel to great achievements in liposome technology, 
led to the design and licensing of liposome formulations for the treatment of certain cancers, 
and the first liposome-based vaccine for use in humans. Finally, liposomes as adjuvants 
became an important attraction with the first liposome-based vaccine (against hepatitis A) 
having been licensed for use in humans (Gregoriadis, 1995). 
However, the first results demonstrated that liposomes were physico-chemically and 
biologically unstable and drug encapsulation was not efficient. Fortunately, great advances in 
liposome technology allowed researchers to make significant improvements in its stability, as 
well as in the understanding of its characteristics and how they interact with biological fluids. 
Several factors have shown direct influence on the behavior of liposomes in a biological 
environment, such as preparation, vesicle size, composition, rate stability and drug 
encapsulation (Lasic, 1998). Thus, methods of characterization and controlling these factors 
became of extreme importance to produce these nanocarriers for drug delivery purposes. 
Similarities between the lipid bilayer structure and the cell membrane, make liposomes 
capable of interacting with the cells, allowing the targeting of the drug to reach the specific 
site, and therefore, with less toxicity than free drugs (McPhail, Tetley, Dufes, & Uchegbu, 
2000). 
Various peptides are used as highly specific and effective therapeutic agents. However, their 
use is complicated by their instability and side effects. Several peptide drugs have their 
therapeutic targets inside cells. Thus, it is important to bring these drugs into target cells 
without subjecting them to lysosomal degradation. 
The use of liposomes as carriers of biomolecules is presented as an important step in the 
production of vaccines or drug-delivery systems, used for controlled delivery of drugs, 
markers for diagnosis, among other applications. In its use in vaccines, liposomes have the 
advantage of being able to maintain antigens (e.g. nucleic material, or small peptides) present 
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in the organism for long enough to obtain an immune response. Otherwise, these 
biomolecules easily degrade, or are rapidly removed from the circulatory system through the 
phagocytic cells of the reticulum-endothelial system (RES) (Takeuchi, Kojima, Yamamoto, & 
Kawashima, 2000), and there is not enough time to obtain an immune response. The antigenic 
materials can be retained on the surface of liposomes, or else could be encapsulated or 
embedded within the membrane. 
Technology related to controlled release of drugs represents one of the frontiers of science. 
Nanocarriers are multifunctional and can contribute significantly to the improvement of 
human health. Drug delivery systems offer a number of advantages when compared to other 
conventional dosage forms. Various applications of nanocarriers have shown positive results. 
Figure 2.6 highlights the major functions of nanocarriers in general and, in particular, 
advantages of liposome-based delivery systems are summarized, to understand why they are 
candidates to this study (Mohanraj & Chen, 2006; Rawat, Singh, Saraf, & Saraf, 2006; Solaro, 
Chiellini, & Battisti, 2010). 
 
 
Figure 2.6 – Multi-functions of liposomes as nanocarriers (adapted from Mohanraj & Chen, 
2006; Rawat, Singh, Saraf, & Saraf, 2006; Solaro, Chiellini, & Battisti, 2010). 
 
Chapter 2  Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML 
14 Fátima Machado 
Understanding liposome-cell interaction processes may facilitate potentiating the desired 
effect of a drug. Many liposomes are made of certain components (e.g. pH-sensitive 
components) so that drug release can occur only in the target site. Figure 2.7 highlights some 
liposome-cell interaction processes already known (Torchilin, 2005).  
 
 
Figure 2.7 – Liposome-cell interaction processes (Torchilin, 2005). 
 
Liposomes can be specifically (a) or nonspecifically adsorbed onto the cell surface. 
Alternatively, they also fuse with the cell membrane (c), and release their content into the cell 
cytoplasm, or can be destabilized by certain cell membrane components when adsorbed on the 
surface (d) so that the released drug can enter cell via micropinocytosis. Direct or transfer-
protein-mediated exchange of lipid components with the cell membrane is another process 
that liposomes can undergo (e) or, instead, be subjected to a specific or nonspecific 
endocytosis (f). In the case of endocytosis, a liposome can be delivered by the endosome into 
the lysosome (g) or, en route to the lysosome, the liposome can provoke endosome 
destabilization (h), which results in drug liberation into the cell cytoplasm (Figure 2.7). 
Figure 2.8 highlights membrane destabilization of liposomes and endosomes (Torchilin, 
2005).  
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Figure 2.8 – Membrane destabilization of liposomes and endosomes (Torchilin, 2005). 
 
After accumulation in required sites in the body, liposomes containing stimuli sensitive 
components, such as lipids (a) in the membrane and drug (b) inside, after being subjected to a 
certain stimulus (such as pH or temperature), liposomes undergo local membrane 
destabilization, consequently drug efflux occurs from the liposome into surroundings (A). 
Destabilization of endosomal membrane (B) occurs after being endocytosed by the cell and 
taken inside the endosome, the liposome containing stimuli (pH)-sensitive components, such 
as lipids (a) in the membrane and drug (b) inside, can undergo pH-dependent membrane 
destabilization and initiate the destabilization (Figure 2.8) of the lysosomal membrane, and 
consequently drug efflux occurs into the cell cytoplasm. 
Besides being prepared entirely synthetically, liposomes have also the benefit of being 
biodegradable, nontoxic and can be administrated in several forms. When immunostimulants 
are incorporated within these tiny particles, the effect of the resulting system will not only be 
an increase of their immunological action, but also a reduction of their toxic side effects. 
Liposomes effect is not only to improve drug action. In fact, many drugs and current classes 
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of therapeutics cannot even cross cell membranes to gain access to their intracellular site of 
action. Liposomes can easily overcome this obstacle. 
Liposomes are versatile structures, in which many characteristics can be manipulated with 
high level of accuracy. Consequently, their immunoadjuvant properties can be handled as 
well. To name some structural characteristics, vesicle size, surface charge, the lipid to antigen 
mass ratio, bilayer fluidity, and the mode of antigen association with lipid vesicles, are all 
factors that can significantly influence adjuvanticity. Marketed liposomal and lipid-based 
products, plus a selection of products in clinical development have been recently reviewed 
(Allen & Cullis, 2013). 
 
2.1.4. DODAC:MO-based liposomes 
There is a class of surfactants suitable to form vesicles in aqueous solutions, and DODAC 
(Figure 2.9) is one example. Dioctadecyldimethylammonium chloride is a synthetic cationic 
surfactant suitable to form vesicles in aqueous solutions. Surfactant concentration, vesicle 
preparation method and solvent condition are aspects to take into account. Optically clear 
dispersions of dioctadecyldimethylammonium chloride are capable of forming LUV by 
simply warming the aqueous surfactant solution (typically 1mM) to 50 °C, above the gel to 
liquid crystalline phase transition temperature, Tm = 48.9 °C (Feitosa, Barreleirob, & 
Olofsson, 2000), and gently shaking it. Cryo-transmission electron microscopy micrographs 
show that DODAX vesicles are unilamellar and polydisperse (Feitosa, Karlsson, & Edwards, 
2006). Feitosa et al, also demonstrated that these vesicles are stable for at least 1 month 
according to the ageing time-dependence of the turbidity and molar absorption coefficient. 
Figure 2.9 shows the structure of DODAC (Eloi Feitosa & Alves, 2008). 
The cationic nature of certain liposomes is an attractive characteristic for drug-delivery and 
gene delivery (Zuhorn, Engberts, & Hoekstra, 2007). Cationic liposomes remain for a longer 
time in circulatory system than negative and neutral liposomes, because cationic formulations 
are able to escape phagocytosis. This ability of cationic liposomes is related to their 
interaction with blood cells (Aoki, Tottori, Sakurai, Fujib, & Miyajima, 1997). The positive 
charge of cationic liposomes exhibit high affinity for the negative charge of cell membrane, 
which facilitates cell uptake (Wiethoff, Smith, Koe, & Middaugh, 2001), and may be used for 
the release of exogenous genetic material intracellularly (Sharma & Sharma, 1997). 
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Apparently, cationic microparticles are optimal for uptake into macrophages and dendritic 
cells (DC) (Thiele, Merkle, & Walter, 2003). 
 
 
Figure 2.9 – Chemical structure of DODAC (Thiele, Merkle, & Walter, 2003). 
 
Despite promising candidates to effectively enhance immune responses (Christensen et al., 
2007; Nakanishi et al., 1999), cationic liposomes may have an immunotoxic effect (Kedmi, 
Ben-Arie, & Peer, 2010; Lv, Zhang, Wang, Cui, & Yan, 2006), limiting their safety for 
clinical use. This brings to mind the importance of an ideal liposome/antigen formulation, 
with characteristics that have to be tuned to reach the most effective and harmless formulation 
as possible. 
Monoolein, 1-monooleoil-rac-glycerol (MO), is a natural amphiphilic neutral single tail 
unsaturated lipid that assembles in water, as it has the particularity to form two non-lamellar 
inverted bicontinuous cubic phases (QII
G
 and QII
D
 ) even in excess H2O (Ericsson, Larsson, & 
Fontell, 1983; Geil et al., 2000). Since the 1960s there has been a steady increase in 
publications, industrial applications and related patents (Kulkarni, Wachter, Iglesias-Salto, 
Engelskirchen, & Ahualli, 2011).  
From the molecular point of view, despite being a simple molecule, it shows amphiphilic 
properties as it contains a polar head group and a nonpolar hydrocarbon chain. It is composed 
of a hydrocarbon chain, which is attached to a glycerol backbone by an ester bond. The 
remaining two hydroxyl groups of the glycerol moiety confer polar characteristics to this part 
of the molecule commonly referred as the head group. Thus, they may form hydrogen bonds 
with water in aqueous solutions. In contrast, the C18 hydrocarbon chain (usually referred as 
the ‘tail’), featuring a cis double bond at the 9, 10 position, is strongly hydrophobic (Kulkarni 
et al., 2011). Consequently, this allows monoolein molecules to self-assemble into different 
liquid crystalline structures under varying conditions of temperature and solvent composition 
(Ganem-Quintanar, Quintanar-Guerrero, & Buri, 2000). 
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Figure 2.10 shows the chemical structure of monoolein.  
 
 
Figure 2.10 – Chemical structure of monoolein (Kulkarni, Wachter, Iglesias-Salto, 
Engelskirchen, & Ahualli, 2011)  
 
Cubic phases are known to play an important role in many cell processes, such as membrane 
fusion (Luzzati, 1997), protein function (Epand, 1998) and ultra-structural organization 
(Lipowsky & Sackmann, 2004), and DNA condensation in lipoplexes (Silva, Coutinho, & 
Oliveira, 2008, 2011). 
Therefore, MO has become a preferential model for the study of a broad range of applications.  
MO is a non-bilayer-forming surfactant that favors vesicle formation. New reported results on 
this subject indicate that both temperature and MO tendency to form non-bilayer structures 
largely influence the self-assembly process, affecting the structure of the final aggregates 
(Oliveira et al., 2012). 
Overall, this study may provide further insight on the relationship between delivery efficiency 
and structural organization of peptide/DODAC:MO complexes. Different formulations of 
peptide/DODAC:MO will certainly affect the structural organization of the final particle. This 
will all be extensively studied. The potential of the system DODAC/MO has motivated this 
investigation. Monoolein is a nontoxic, biodegradable, and biocompatible material classified 
as GRAS (generally recognized as safe). Its biodegradability is due to the fact that monoolein 
is subject to lipolysis because of different kinds of esterase activity in different tissues.  This 
remarkable molecule is particularly interesting due to its nature and physicochemical 
behavior, which makes it an attractive alternative in relation to other conventionally used 
materials. The most significant advantages of monoolein are probably its solubilizing 
capability, rheological behavior, and low toxicity. Furthermore, the versatility of monoolein 
makes possible to include it in very different systems and cubic phase reveals great flexibility 
since drugs of very different polarity and size may be accommodated within it. 
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2.2. Chronic Myeloid Leukemia 
Chronic myeloid leukemia (CML) is a malignant disorder that originates in a single abnormal 
hematopoietic stem cell. The anomalous clone originated from this cell expands and infiltrates 
the medullar parenchyma, slowly but progressively, over the proliferation of normal cells. The 
disease is associated with a specific cytogenetic abnormality, the Philadelphia chromosome 
(Ph), resulting from a reciprocal translocation between the long arms of chromosomes 9 and 
22 t(9;22)(q34;q11) that leads to the formation of a new leukemia-specific gene, BCR-ABL, 
generated by the fusion of the c-abl oncogene 1 (ABL1, from chromosome 9) with the 
breakpoint cluster region gene (BCR, from chromosome 22). In CML, the second or third 
exon of the BCR gene is usually spliced into the second exon of the ABL gene, creating 
B2A2 or B3A2 transcripts. Once translated, each B2A2 or B3A2 mRNA generate a 210-kDa 
BCR-ABL protein. The BCR-ABL fusion protein shows tyrosine kinase activity and is 
essential and sufficient for leukemia transformation and progression. In fact, the junctional 
sequences of BCR-ABL are only expressed in leukemia cells (Pinilla-Ibarz et al., 2000). This 
constitutively up regulated tyrosine kinase activity of the chimeric BCR-ABL1 protein affects 
several intracellular signaling pathways that promote proliferation and survival of cells and 
thus contribute to their malignant transformation (Guilhot et al., 2008; Quintás-Cardama & 
Cortes, 2009; Smahel, 2011). Under normal conditions, the BCR gene expressed on 
chromosome 22 encodes a protein whose function is related to cell cycle regulation, whereas 
gene ABL expressed on chromosome 9 encodes a protein tyrosine quinase (Druker et al., 
2001). The reciprocal gene resulting from translocation ABL-BCR on chromosome 9q+, 
though active, plays no role in any kind of disease. The hybrid gene BCR-ABL produces a 
chimeric protein with elevated tyrosine kinase activity. The disease begins with a chronic 
phase (CP) that can last for 3 to 5 years, and if untreated, it progresses into accelerated phase 
(AP) and within a year, blast phase (BP). Survival at this point is less than 1 year. 
CML patients were once regarded as incurable, but more recent understanding of the 
molecular anatomy and pathophysiology of the disease provides important insights into the 
targeting of treatment to a specific molecular abnormality. CML has been recognized as a 
potent model for immune therapy in humans because there is a specific gene rearrangement, 
BCR/ABL, which product, P210bcr/abl can be the target antigen for immune therapy. 
Peptides spanning the junction between BCR and ABL in P210bcr/abl are specific to CML 
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cells; they are not present in other normal cells neither in CML patients nor in cells in normal 
individuals without CML (Guilhot et al., 2008). 
Despite the therapeutic advances that made possible the significant increase in the perspective 
of life in patients with CML, several biological mechanisms that favor the selection of 
malignant cells over normal cells have been responsible for treatment failure in many cases 
(Bergantini, Castro, Souza, & Fett-conte, 2005).  
Because the preeminent mutation driving CML is BCR-ABL, therapies targeting this gene are 
the logical choice for disease-specific therapy directed at the BCR-ABL tyrosine kinase. 
However, even in the best responders residual leukemic cells may persist. Since these 
therapies fail to eradicate the CML stem cells, much work still has to be done and 
improvement or development of new and more effective strategies would be useful. 
 
2.2.1. Vaccination with BCR-ABL 
The breakpoint in the bcr gene occurs either between bcr exon 2 (b2) and 3 (b3) or between 
bcr exon 3 (b3) and 4 (b4). Hence, 2 alternative chimeric p210 bcr-abl proteins, comprising 
either a b3a2 or a b2a2 junction, can result from this fusion gene (Shtivelman, Lifshitz, Gale, 
Roe, & Canaani, 1986). The cellular processing of the products of these two fusion proteins 
can originate peptides capable of being presented in the cell surface, and can be recognized by 
cytotoxic T-lymphocytes (CTL) in the context of human leukocyte antigen (HLA) class I 
molecules (Falkenburg, Smit, & Willemze, 1997; Melief & Kast, 1995). Thus, despite the 
intracellular location of p210, those peptides can be recognized by T cells within the cleft of 
HLA. For this reason, and considering that the junction between the fused BCR and ABL 
genes produces a novel peptide sequence that is unique to leukemic cells, it is a reasonable 
target for leukemia specific immunotherapy. A list of BCR-ABL peptides used in vaccine 
trials in patients with chronic myeloid leukemia has been reviewed (Dao & Scheinberg, 
2008). Furthermore, there are three different forms of the Bcr-Abl oncogene p185, p210, and 
p230 (Melo, 1996), which may represent alternative potential targets for immunotherapy 
approaches (Volpe et al., 2007). 
In Bocchia et al. (2010) documented clinical trial, one patient was treated with a target 
immune approach receiving a therapeutic vaccine. This vaccine consisted of a 25-mer b2a2 
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breakpoint derived peptide (CMLb2a2-25) with binding properties for several HLA-DR 
molecules and was able to elicit a consistent peptide-specific CD4
+
 T-cell response. This 
study shows, for the first time, that these peptide vaccinations were able to reduce and even 
eradicate minimal residual disease in a patient with CML. 
Hereupon, the present work emerges in an attempt to find an alternative target approach that 
can be added to CML currently used therapy to eradicate minimal residual disease through 
immunotherapy. The approach described in this thesis consists of a liposomal peptide vaccine. 
Because several peptides can be encapsulated in lipid vesicles, one day this strategy may be 
used as a multitherapeutic therapy. This concept provides a new paradigm for the treatment of 
CML, and CMLb2a2-25 peptide used in Bocchia et al. (2010) trial will be studied in the 
present work. 
 
2.2.2. The b2a2 breakpoint derived peptide 
A therapeutic vaccine consisted of a 25-mer b2a2 breakpoint derived peptide (CMLb2a2-25) 
tested in a 63-year old woman with chronic myeloid leukemia was able to elicit a consistent 
peptide-specific CD4
+
 T-cell response (Bocchia, Defina, & Aprile, 2010). This resulted in a 
reduction and even eradication of minimal residual disease.  
CMLb2a2 peptide has sequence of 25 amino acids (3-letter code), Thr-Val-His-Ser-Ile-Pro-
Leu-Thr-Ile-Asn-Lys-Glu-Glu-Ala-Leu-Gln-Arg-Pro-Val-Ala-Ser-Asp-Phe-Glu-Pro-NH2, 
whose properties can be seen in Table 2.1 and Table 2.2. Figure 2.11 shows a representation 
of the CMLb2a2-25-25mer peptide that is going to be used in the present study. 
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Figure 2.11 – Representation of CMLb2a2-25mer peptide: A – Chemical bonds are denoted 
for Carbon (grey), Nitrogen (blue), Oxygen (red) and Hydrogen (white); B – molecule’s 
solvation area. The molecular properties of this peptide were attained by ChemBioOffice 13 
program, developed by Cambridge Software. 
 
The present thesis comprises a study of this peptide in different pH conditions. In order to 
support and interpret results, few properties as charge, hydrophobicity, pKa and isoelectric 
point (pI) should be elucidated (HubPages, 2013; Publishing, 2013). First we must know the 
amino acid structure. Figure 2.12 shows a representation of an amino acid. 
Figure 2.12 – Amino acid structure (adapted from Hambly, 2013). 
The alpha-carbon (center) in an amino acid: 
- Is bonded to an amino group 
- Is bonded to a carboxyl group 
- Is bonded to a hydrogen 
- Is bonded to a side chain group (R) 
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Peptide bonds allow amino acids to be linked, consequently forming peptides. This peptide 
bond consists of a carbonyl group's carbon atom directly bound to the nitrogen atom of a 
secondary amine. After the peptide formation, the peptide chain will have an unbound amino 
group free at one end, called the N-terminus, and a single free carboxylate group at the other 
end, named the C-terminus. 
Amino acids can be classified, among other aspects, according to the side chain group (R). 
Since amino acids, peptides, and proteins have different pKa values, there is the possibility 
that they can have different charges at a given pH.  
Table 2.1 shows the properties of the amino acids included in CMLb2a2 peptide, and the 
respective pka and pI are shown in Table 2.2. 
 
Table 2.1 – Amino acids properties. 
Amino 
Acid 
3-letter 
code 
Properties Amino 
Acid 
3-letter 
code 
Properties 
Alanine Ala aliphatic 
hydrophobic 
neutral 
Leucine Leu aliphatic 
hydrophobic 
neutral 
Arginine Arg polar 
hydrophilic 
charged (+) 
Lysine Lys polar 
hydrophilic 
charged (+) 
Asparagine Asn polar 
hydrophilic 
neutral 
Phenylala-
nine 
Phe aromatic 
hydrophobic 
neutral 
Aspartate Asp polar 
hydrophilic 
charged (-) 
Proline Pro hydrophobic 
neutral 
Glutamine Gln polar 
hydrophilic 
neutral 
Serine Ser polar 
hydrophilic 
neutral 
Glutamate Glu polar 
hydrophilic 
charged (-) 
Threonine Thr polar 
hydrophilic 
neutral 
Histidine His aromatic 
polar 
hydrophilic 
charged (+) 
Valine Val aliphatic 
hydrophobic 
neutral 
Isoleucine Ile aliphatic 
hydrophobic 
neutral 
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Table 2.2 – Buried and surface amino acids, and the respective pka and pI, included in the 
peptide CMLb2a2 peptide. 
Burried Surface 
Amino Acid pka pI Amino Acid pka pI 
Alanine - 6.0 Glutamate 4.3 3.22 
Valine - 5.96 Lysine 10.5 9.74 
Phenylalanine - 5.48 Glutamine - 5.65 
Leucine - 5.98 Proline - 6.30 
Isoleucine - 6.02 Serine - 5.58 
- 
  
Threonine - 5.60 
- 
  
Aspartate 3.7 2.77 
- 
  
Histidine 6.0 7.59 
-   Arginine 12.5 10.76 
-   Asparagine - 5.41 
 
An atom group in a molecule may lose or gain a proton when the molecule is placed in an 
aqueous solution. The exact probability that a molecule will be protonated or deprotonated 
depends on the pKa of the molecule and the pH of the solution. Half of molecules will lose 
protons if they are in a solution with pH = pKa. The higher the pH value, the more likely a 
molecule will lose a proton (Publishing, 2013). Furthermore, from the definition of pH, a high 
concentration of HO
-
 ions is present at higher pH, thereby being capable of accepting more 
protons which results in the neutralization of positive charges. 
As for the isoelectric point, when the pH is lowered far below the pI, the protein will lose its 
negative charge and will contain only positive charges, but if the pH is adjusted to the 
isoelectric point of the protein, its net charge will be zero. Most proteins at physiological pH 
are above their pI, thereby having an overall negative charge. This information, along with 
table 2, suggests that at neutral pH, BCR-ABL peptide has a net negative charge. 
By observing table 2 it can be noted that pKa is not shown for certain amino acids. The pKa 
essentially refers to the tendency for H
+
 to dissociate from a molecule, and thus is a measure 
of the extent of H
+
 dissociation under equilibrium conditions. So, if a molecule's hydrogen has 
no tendency to dissociate, then it will not have a pKa. The R groups of such amino acids have 
no dissociable hydrogens - these groups are neither acids nor bases. It should be noted that we 
are referring strictly to the R-groups, because even the neutral amino acids still have a pKa for 
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the backbone of amino and carboxyl groups. The carboxyl group has a pKa ranging from 1.8 
to 2.4 and is most likely negatively charged at neutral pH, whereas the amino group has a pKa 
ranging from 8 to 11 and is most likely positively charged. 
From Table 2.2 we can also infer that the peptide charged amino acids are characterized as 
being surface amino acids. Therefore, all these charges will be considered when predicting 
and analyzing the surface charge of the BCR-ABL peptide at different pH conditions. 
From Table 2.1 and Table 2.2 we can observe that four negatively charged (Glu (3x) and Asp) 
and three positively charged (Lys, Arg and His) amino acids are included in this peptide. 
Thus, it is expected that this peptide will exhibit a negative overall charge which will be 
attracted for the positively charged membranes of liposomes (Friede, Vanregenmortel, & 
Schuber, 1993; Gregory Gregoriadis, 2007a). Additionally, the amphipathic character of this 
peptide may increase its affinity for biological membranes (Bessalle et al., 1993; Wimmer et 
al., 2006). 
CMLb2a2 peptide contains two amino acids with beta strands, Val and Ile, and two amino 
acids with alpha helix, Ala and Leu. The special conformation of these amino acids may play 
an important role in the interaction with lipid membranes and affect peptide incorporation into 
liposomes. However, the interaction with liposomes can stabilize the alpha helix structure 
(Bessalle et al., 1993; Wimmer et al., 2006). 
This peptide has a preference for secondary structures and contains 48% of hydrophobic 
amino acids, 16%, 12% and 24% of acidic, basic and neutral amino acids, respectively. 
Peptide molecular formula is C124H200N34O39, has a molecular weight of 2790,47 g/mol and a 
molecular volume of 3377,307 Å
3
. 
From the information above we can predict the amino acids charge and, consequently, the 
overall surface charge of BCR-ABL peptide at acidic, neutral and alkaline pH (Table 2.3). It 
should be noted that histidine (His) is very sensitive to pH change in the physiological range. 
The R group of histidine (pKa = 6.0) has only 10% probability to become positively charged 
at pH = 7, but the probability increases to 50% at pH = 6. Therefore, histidine will not be 
considered as positively charged at neutral and alkaline pH. 
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Table 2.3 – Positively and negatively charged amino acids for CMLb2a2 peptide at acidic 
(pH=4), neutral (pH=7) and alkaline (pH=9) pH conditions, according to pKa. Amino and 
carboxyl groups placed at the two extremes of the peptide are also considered. 
pH condition 4 7 9 
Charge Negative Positive Negative Positive Negative Positive 
Amino Acids 
- Lys Glu Lys Glu Lys 
- Arg Glu Arg Glu Arg 
- His Glu - Glu - 
Asp - Asp - Asp - 
Carboxyl/Amino 
groups 
carboxyl - carboxyl Amino carboxyl - 
Total 2 3 5 3 5 2 
 
Considering the information from table 3, and considering that at acid pH the excess of H
+ 
ions is capable of neutralizing peptide negative charges and that at alkaline pH the excess of 
HO
-
 is capable of neutralizing peptide positive charges, we can expect that the peptide 
negative surface charge will be stronger at pH 7 and 9, than at pH 4. 
Amino acids properties described above are of major importance since factors affecting 
peptide–liposome membrane interactions include effects of peptide length, charge, 
hydrophobicity, secondary structure, and topology (Strömstedt, Ringstad, Schmidtchen, & 
Malmsten, 2010). 
CMLb2a2 peptide incorporation into liposomes will be analyzed using specific techniques 
described in chapter 3. 
 
2.3. Liposomal vaccines 
Extensive information about the use of liposomes as immunological adjuvants for protein and 
peptide antigens is available since the early 90s (G. Gregoriadis, Florence, & Patel, 1993; 
Philippot & Schuber, 1995). When peptide antigens are encapsulated in lipid vesicles, the 
liposome-peptide complexes formed are phagocytosed by macrophages. Eventually, 
liposome-peptide systems accumulate in lysosomes, where the encapsulated peptides are 
presented to the MHC class II complex. At this stage, the system is capable of stimulating 
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specific T-helper cells (Philippot & Schuber, 1995). This constitutes the basis for the use of 
lipid vesicles as adjuvants in vaccine development. Among many other reports, Maiko 
Taneichi et al (Taneichi et al., 2006) conducted a study in which liposomes were presented to 
both CD4
+
 and CD8
+
 T cells, and potent antitumor immunity was induced.  
Although a similar approach in not apparently available for CML, liposomes have been 
successfully used in peptide vaccines, as they were capable of protecting and delivering the 
peptide in the proper target and elicit strong antigen-specific T- responses (Chikh, Kong, 
Bally, Meunier, & Schutze-Redelmeier, 2001; Copland et al., 2003; Guan et al., 1998; 
Ludewig et al., 2000; Masuda, Horie, Suzuki, Yoshikawa, & Hirano, 2002; Rao & Alving, 
2000). 
Other important aspect to take into account is that the adjuvant effect of cationic liposomes 
depends on administration route. Han-Chung Wu and De-Kuan Chang’s (Wu & Chang, 2010) 
work elucidates the molecular mechanism of peptide-conjugated liposomes on cancer therapy. 
In the intravenous route, the immune system can easily recognize lipid vesicles, which are 
then cleared from circulation by phagocytes. Furthermore, the desired concentration of a drug 
in blood is obtained with an accuracy and speed that are not possible with other procedures. 
This is of major importance since in CML malignant cells are not localized in a specific 
region, instead, they are scattered throughout the organism. Therefore, this is an important 
aspect to be taken into account when developing the nano-system, and intravenous 
administration should be the proper approach to the aim of this thesis. 
High doses of a drug may be severely detrimental to the patient, whereas small doses may be 
insufficient to eradicate the tumor. This is the main reason why most cancer drugs are 
ineffective in killing cancer cells. In this context, liposomes emerge as a successful alternative 
to overcome the problem. A clinical study in which a drug was encapsulated in liposomes 
reported that these lipid vesicles were able to retain the drug within it while circulating in 
blood stream (Orlowski et al., 2007). This makes possible to deliver the drug to the target 
without leakage from the liposomes, dramatically reducing side effects during its journey to 
the tumor tissues, and improving the index of a drug. 
When producing liposome-delivery chemotherapy agents, the hyper permeability of tumor 
vasculature should be taken into account. The size of the liposome is a key-factor to succeed 
when developing a treatment strategy (Fifis et al., 2004; Mottram et al., 2007). Gap junction 
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found in normal endothelium are typically <6nm wide (Drummond, Meyer, Hong, Kirpotin, 
& Papahadjopoulos, 1999), and liposomes with 65-75nm diameters were found to be large 
enough to be excluded from normal endothelium and at the same time small enough to 
infiltrate tumor endothelium (T. Lee, Wu, Tseng, & Lin, 2004; T.-Y. Lee, Lin, Kuo, Chang, & 
Wu, 2007; Lo, Lin, & Wu, 2008). On the other hand, angiogenic tumor vasculature is 
estimated to have an average pore size of 100 – 600 nm (Hashizume et al., 2000), which is 
significantly larger than the normal endothelium. Thus, the proper size of the liposome is 
crucial to protect normal cells and tissues, and to deliver the drug to the target as they 
selectively reach the tumor interstitial space. 
The advantage of liposomes to protect the drug from the body and to protect the body from 
the drug, retaining it during a period of time, associated with the advantage of the tumor 
vasculature’s high permeability, turns this approach into a potential treatment for various 
cancers. Furthermore, liposomes may be retained longer in tumor tissues as it frequently lacks 
effective lymphatic drainage (Jain, 1987). In this respect, a new term known as “enhanced 
permeability and retention (EPR) effect” was first adopted by Matsumura & Maeda (1986), 
consisting in higher accumulation of a certain drug within the tumor. This becomes much 
more important when results concerning liposome delivery systems show a ten times higher 
effect, compared to free drugs (Northfelt et al., 1996). 
To further enhance the selectivity and concentration of liposomes within the tumor region, 
peptides can be previously attached to the lipid vesicles. After intravenous administration, 
liposomes arrive to the tumor tissues where they are internalized by tumor cells through 
receptor-mediated endocytosis. Eventually, liposomes are broken down so that the 
encapsulated drug is released within the intracellular space of the cells. Diagram presented in 
Figure 2.13 may clarify the molecular mechanism of peptide-conjugated liposomes on cancer 
therapy. 
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Figure 2.13 – Representation of the molecular mechanism of peptide-conjugated liposomes on 
cancer therapy (Wu & Chang, 2010). 
 
The development of ‘pharmaceutical’ liposome-based delivery systems is an area of intense 
research currently, as new promising treatments may arise from it. The increasing variety of 
encouraging results reported in numerous clinical trials concerning many different diseases 
supports the revolutionary role of lipid vesicles in modern medicine. 
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2.3.1. Role of adjuvants in vaccine development 
The first definition of immunological adjuvants was first reported in the 20
th
 century (Ramon, 
1924) as "substances used in combination with a specific antigen that produced a more robust 
immune response than the antigen alone." In other words, immunological adjuvants are 
molecules or substances capable of amplifying or enhance the cascade of immunological 
events that comprise the immune response (Schijns, 2000). Moreover, it should also induce 
antigens to elicit an early, high and long-lasting immune response with a smaller amount of 
antigen, by modulating the immune system (Audibert, 2003), and direct this immune response 
to a protective response, preventing the disease reappearance (Morein, Villacrés-Eriksson, 
Sjölander, & Bengtsson, 1996). In other words, adjuvants are molecules that accelerate and 
increase antigen-specific immune responses. 
Peptide-liposomal vaccines are often poorly immunogenic and effective vaccines are not 
available against a number of important diseases at the present time. To be successful against 
the most difficult pathogens, vaccines must induce more potent immune responses. 
Specifically, cellular immune responses include induction of cytokines from CD4
+
 T helper 
cells and CD8
+
 cytotoxic T lymphocytes. 
As traditional vaccines may not be successful as it is desired to, vaccine adjuvants may be 
required to achieve significant improvements, so that these new-generation vaccines can be 
effective against the most difficult diseases. Novel adjuvants together with vaccine delivery 
systems will enable the development of new-generation vaccines against diseases thought 
incurable today. 
Nevertheless, adjuvant safety remains a significant concern. The level of adjuvant toxicity is a 
key issue in adjuvant development, since adjuvants that induce a certain degree of adverse 
effects will not prove acceptable. The potential use of an adjuvant will be based on its safety - 
if it induces minimal adverse effects – and on its strength, when in association with a certain 
molecule. In fact, most adjuvants that have proceeded to clinical trials have proven to be too 
toxic for clinical use. Other important characteristics to consider include stability, 
biodegradability, cost, ease of manufacture, and applicability to a wide range of vaccines. 
In its use in antigen vaccines, adjuvants are useful to improve immune response to vaccine 
antigens in various different ways (Schinjs & T.O’Hagan, 2006), including: (i) enhancing the 
speed and duration of the immune response; (ii) stimulating cellular immunity, including the 
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desired cytokine profile; (iii) increasing the immunogenicity of weak antigens; (iv) 
modulating antibody avidity, specificity, isotype, or subclass distribution; (v) promoting the 
induction of mucosal immunity; (vi) decreasing the dose of antigen in the vaccine to reduce 
costs; (vii) enhancing immune responses in immunologically immature, or senescent 
individuals; (viii) helping to overcome antigen competition in combination vaccines. 
The mechanisms of action of adjuvants remains poorly understood. However, the 
identification of key receptors of the innate immune system made possible to achieve 
significant advances. Two broad groups can be distinguished based on their principal modes 
of action (Schinjs & T.O’Hagan, 2006), focusing on whether or not they have direct 
immunopotentiating effects on innate immune cells, or they function primarily as "delivery 
systems" to promote antigen uptake into antigen-presenting cells (APC). Liposomes are 
among these adjuvants. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
(Page intentionally left blank)  
  
Chapter 3 
Methodologies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The most exciting phrase to hear in science, the one that heralds new discoveries, is not 
“Eureka!” (I found it!) but “That’s funny…” ”  
Isaac Asimov (1920 – 1992) 
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3. CHAPTER 3  METHODOLOGIES 
3.1. Materials 
The synthetic peptide, CMLb2a2-25, with an aminated C-terminus 
(TVHSIPLTINKEEALQRPVASDFEP-NH2), with a purity of 96.10%, was purchased from 
Caslo (Denmark). Dioctadecyldimethylammonium chloride, DODAC, was purchased from 
Tokyo Kasei (Japan). 1-monooleoyl-rac-glycerol (MO) was purchased from Sigma-Aldrich 
(USA). Disposable polysterene cuvettes were purchased from Sarstedt (Germany). Disposable 
Zeta DIP cells were purchased from Malvern (UK). Nucleopore Track-Etch Membrane filters 
(200 nm) were acquired from Whatman (UK), and Amicon Ultra-15 Centrifugal Filter Units 
(50 000 NMWL) were purchased from Milipore (USA). 
Human THP-1 cell line was purchased from ATCC (USA). Coating mAb (TNF3/4), 
Detection mAb (TNF5-biotin) and Streptavidin-ALP included in ELISA KIT for human TNF-
α, were purchased from Mabtech (Sweden). Albumin from bovine serum (BSA) and Alkaline 
Phosphatase Yellow (pNPP) liquid substrate system for ELISA were purchased form Sigma-
Aldrich (USA). Tissue culture test plates were purchased from TPP (Switzerland). 
 
3.2. BCR-ABL peptide analyses 
A citrate-phosphate buffer (150 mM KCl; 10 mM KH2PO4; 10 mM H3BO4 and 10 mM Na-
citrate) was used to prepare peptide solutions at different pH (4, 7.2 and 9). Citrate-phosphate 
buffer has a pH ranging from 3 to 10 which makes this a suitable buffer to study peptide or 
liposome behavior in acidic, neutral and alkaline environments without changing the buffer. 
HEPES buffer, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, at pH=7.2 (10 mM) was 
also used for comparison. HEPES has a pH ranging from 6.8 to 8.2, therefore, it cannot be 
used to study BCR-ABL peptide in strongly acidic or alkaline conditions. Nevertheless, this 
buffer is largely used in cell culture because it is better at maintaining physiological pH 
despite changes in carbon dioxide concentration, and at pH=7.2 would be suitable to mimic 
body fluids such as human blood stream.  
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Three peptide concentrations (10 µg/mL, 20 µg/mL and 40 µg/mL) were analyzed through 
DLS assays described in section 3.4, before and after sonication which is also described 
below. 
3.3. Nanoparticles preparation 
Peptide/lipid nanoparticles were prepared according to the methods described in section 2.1.2. 
Specific experimental work is described below. 
A) Lipid film hydration / sonication 
(i) Direct insertion 
The DODAC:MO (1:2) lipid film at different lipid concentrations was first obtained by 
pipetting the adequate volumes of DODAC and MO ethanolic solutions (20 mM), previously 
prepared,  to different test tubes. The ethanol solvent of the preparations was evaporated 
under nitrogen stream to obtain a homogenous lipid film. Then, 5 mL of peptide solution at a 
concentration of 0,01 mg/mL was added to the test tubes to hydrate the lipid films, allowing 
the peptide encapsulation in newly formed DODAC:MO liposomes at different concentrations 
(Figure 3.1 B). Thus, it was studied the peptide encapsulation at different peptide/lipid ratios. 
The preparations were then submitted to 5 consecutive cycles of a process in which they were 
vigorously vortexed and the exposed to 30 seconds of sonication. 
(ii) Post-insertion 
For replicates preparation, the lipid film lipid film was hydrated with 2.5 mL of HEPES and 
submitted to vortex and sonication, as mentioned. These replicates were then incubated with 
2,5 mL of a peptide solution (0.02 mg/mL), so that we could obtain solutions at a final 
concentration of 0.01 mg/mL (Figure 3.1 A). These samples were left at 50°C for an hour 
before being analyzed. 
B) Ethanolic injection 
(i) Direct-insertion 
Defined volumes taken from previously prepared stock solutions of DODAC (20 mM) and 
MO (20 mM) in ethanol, were injected in 5 mL of peptide solution, preheated to 50ºC, under 
vigorous vortexing (Figure 3.1 D). The organic solvent (ethanol) evaporates when it comes in 
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touch with the water due to the heat. The solutions obtained are mostly composed of multi-
vesicular liposomes. 
(ii) Post-insertion 
Replicates were prepared in which the desired volume of lipid was injected in 2,5 mL of 
HEPES preheated to 50ºC, under vigorous vortexing. After this, 2,5 mL of a peptide solution 
(0,02 mg/mL) was added, so that we obtained solutions at a final concentration of 0,01 
mg/mL (Figure 3.1 C). These samples were incubated with the peptide solution for a few 
hours, at room temperature, before being analyzed. 
C) Extrusion 
All the solutions obtained from all methods were submitted to an extrusion process in a 
Northern Lipids Lipex Extruder. Under a 4-8 bar pressure, the liposomes were forced to pass 
through polycarbonate filters with a defined pore size. In this case, the liposomes were 
submitted to five passages through a filter with a pore size of 200nm, at a temperature of 
50°C. Multi-lamellar vesicles were transformed in large uni-lamellar vesicles using methods 
A and B schematized in figure 3.1. When multi-vesicular vesicles prepared by methods C and 
D pass through an extrusion filter, their enclosured vesicles are released, however, smaller 
multi-vesicular vesicles are still in the extruded preparation. 
 
3.3.1. Preparation of liposomes for hydration and injection method 
When preparing liposomes with mixed lipid composition, the lipids must first be dissolved 
and/or mixed in an organic solvent to assure a homogeneous mixture of lipids. In this work, 
DODAC and MO are dissolved in ethanol, separately, properly sealed and stored at 4°C. 
Depending on the peptide/lipid ratio desired to be tested and considering the ratio 
DODAC/MO (1:2), the corresponding amount of DODAC and MO are mixed. 
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3.3.2. Preparation of nanoparticles by post-insertion and direct-
insertion 
Five different methodologies were tested in order to compare and decide which one is more 
suitable to the purpose of this work (Figure 3.1). This section aims to clarify the strategies 
adopted: post-insertion and direct insertion. 
(i) Post-insertion and direct-insertion 
Figure 3.1 shows a representation of the different methodologies applied in this work to attach 
peptide molecules to lipid vesicles. 
 
Figure 3.1 – Representation of the different methodologies applied in this work to encapsulate 
peptide molecules in lipid vesicles: A - Preparation of liposomes by lipid film hydration 
before adding peptide solution; B - Preparation of liposomes by lipid film hydration with 
peptide solution being added before lipid vesicles are formed; C - Preparation of liposomes by 
ethanolic injection before adding peptide solution; D - Preparation of liposomes by ethanolic 
injection hydration with peptide solution being added before lipid vesicles are formed 
(courtesy from João Neves - adapted). 
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Briefly, DODAC:MO (1:2) liposomes at different concentrations were prepared by lipid thin 
film hydration (Fig.3.1 A and B) and by ethanolic injection (Fig.3.1 C and D). In both 
methods, two different nanoparticles were obtained as the peptide solution could be added 
before or after lipid vesicles were formed, which may be referred as direct-insertion protocols 
(Fig.3.1 B and D) and post-insertion protocols (Fig. 3.1 A and C). 
 
(ii) Effect of MLV liposomes and LUV liposomes in the final nanoparticle 
Adding the peptide to the particles that were previously submitted to a process of extrusion is 
not the same as adding the peptide to liposomes that have not passed through extrusion. The 
extrusion process is known as being responsible for substances loss (Colletier, Chaize, 
Winterhalter, & Fournier, 2002; Xu, Costa, Khan, & Burgess, 2012). This motivated the 
inclusion of method E: liposomes prepared by lipid film hydration/extrusion followed by 
incubation with peptide after extrusion (Figure 3.2). At the left of figure 3.2 is represented one 
of the four methods described above, method A, and at the right is represented method E.
 
 
Figure 3.2 – Schematic representation of methods: A (left), preparation of liposomes by lipid 
film hydration (1
st
) before adding peptide solution (2
nd
) followed by extrusion (3
rd
); and 
method E (right), preparation of liposomes by lipid film hydration (1
st
) followed by extrusion 
(2
nd
) before adding peptide solution (3
rd
) (courtesy from João Neves – adapted). 
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Two peptide concentrations were tested (10 µg/mL and 20 µg/mL).  By adding appropriate 
amounts of lipid from a stock solution of 20 mM of DODAC and MO concentration different 
peptide/lipid molar ratios were achieved and analyzed (Table 3.1). 
 
Table 3.1 – Total lipid concentration (mM) peptide/lipid molar ratios, for 10 µg/mL and 20 
µg/mL of peptide concentration. 
10 µg/mL of peptide concentration 
[Lipid] (mM) 
peptide-lipid 
molar ratio 
1.75 1/500 
1.05 1/300 
0.875 1/250 
0.7 1/200 
0.35 1/100 
20 µg/mL of peptide concentration 
[Lipid] (mM) 
peptide-lipid 
molar ratio 
1.75 1/250 
 
 
3.4. Biophysical Characterization 
3.4.1. Dynamic Light Scattering assays 
The fate of intravenously injected liposomes is determined by a number of properties. Two of 
the most important are particle size and zeta potential. These techniques are described below.  
“Dynamic light scattering” (DLS), also known as “photon correlation spectroscopy” (PCS) or 
“quasi-elastic light-scattering”, is a process that measures Brownian motion and relates this to 
the size of the particles (Pecora, 2000). Particles suspended in a liquid are never stationary. 
On the contrary, particles are constantly moving due to this Brownian motion, which 
correspond to the random collision with the molecules of the liquid that surrounds the 
particle. But what makes this useful is the fact that small particles move quickly and large 
particles move more slowly. Smaller particles are pushed further by the solvent molecules and 
move more rapidly. When a small particle is illuminated by a laser, it scatters the light in all 
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directions. This way, the laser illuminates the particles and the intensity fluctuations in the 
scattered light are analyzed. The Zetasizer Nano system is capable of measuring the rate of 
the intensity fluctuation and then uses this to calculate the size of the particles (Malvern, 
2005). 
The velocity of the Brownian motion is defined by a property known as the translational 
diffusion coefficient (usually given the symbol, D). The size of a particle, which is related to 
its speed due to Brownian motion, is calculated by using the Stokes-Einstein equation:  
 ( ) / 3d H kT D  (3.1) 
where: 
d (H) refers to the hydrodynamic diameter; D is the translational diffusion coefficient; k is the 
Boltzmann’s constant; T is the absolute temperature and η represents viscosity. 
A typical dynamic light scattering system comprises of six main components, has shown in 
Figure 3.3 (“Size theory,” 2004). Firstly, a laser (1) provides a light source to illuminate the 
sample contained in a cell (2). For dilute concentrations, most of the laser beam passes 
through the sample, but some is scattered by the particles within the sample at all angles. A 
detector (3) is used to measure the scattered light. In the Zetasizer Nano series, the detector 
position will be at either 173° or 90°, depending upon the particular model. 
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Figure 3.3 – Optical configurations of the Zetasizer Nano series for dynamic light scattering 
measurements (Malvern, 2005). 
 
DLS is a convenient method to stability studies. Periodical DLS measurements of a sample 
can show the tendency to particles aggregation and sedimentation over time by seeing 
whether the hydrodynamic radius of the particle increases. If particles aggregate, there will be 
a larger population of particles with a larger radius (Schaffazick & Guterres, 2003). 
 
3.4.2. Zeta (ζ) Potential assays 
An efficient method to study the modification of particles surface is determining the zeta 
potential of nanoparticles in an aqueous environment. Briefly, the zeta potential is the overall 
charge a particle acquires in a particular medium. Both size and zeta potential can be 
measured on the same instrument that calculates the zeta potential by determining the 
Electrophoretic Mobility and then applying the Henry equation. The electrophoretic mobility 
is obtained by performing an electrophoresis experiment on the sample and measuring the 
velocity of the particles using Laser Doppler Velocimetry (LDV) (Malvern, 2005). Zeta 
potential measures the magnitude of the repulsion or attraction between particles charge. This 
measurement provides detailed information on dispersion and aggregation. 
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Knowledge of the zeta potential of a liposome preparation can help to predict the fate of 
liposomes in vivo. Any subsequent modification of the liposome surface can also be 
monitored by measurement of the zeta potential. 
Due to their small size, the forces interacting on the surface of nanoparticles and in the 
dispersion liquid determine its behavior. Each particle may contain an electrical charge that 
can be positive or negative. If a particle is negative, it makes the positive ions in solution 
(called counter-ions, ions of opposite charge to that of the particle) to form a rigid layer 
around its adjacent surface; this layer of counter ions is known as Stern layer. Other positive 
ions may be attracted by the negative particle, but now they are repelled by the Stern layer. A 
dynamic equilibrium occurs and this results in the formation of a diffuse layer of counter-ions, 
which decrease with increasing distance from the surface of the particle. Thus an electrical 
double layer exists around each particle. Within the diffuse layer there is a notional boundary 
inside which the ions and particles form a stable entity. When a particle moves (e.g. due to 
gravity), ions within the boundary move with it, but any ions beyond the boundary do not 
travel with the particle. This boundary is called the surface of hydrodynamic shear or slipping 
plane, and the potential that exists at this boundary is known as the Zeta potential (Figure 
3.4)(Malvern, 2005). 
 
Figure 3.4 – Schematic representation of the double layer surrounding a particle in suspension 
(Malvern, 2005). 
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An individual particle and its associated ions move through the solution as a unit, and the 
potential at the border of the unit, Zeta potential can be measured in a simple manner, while 
the superficial charge cannot. 
 
3.4.3. Electrophoresis and Electrophoretic Mobility 
Electrophoresis consists on the migration of charged particles when an electric field is applied 
across an electrolyte. When this happens, charged particles suspended in the electrolyte are 
attracted towards the electrode of opposite charge. Viscous forces acting on the particles tend 
to oppose this movement (Figure 3.5). When equilibrium is reached between these two 
opposing forces, the particles move with constant velocity. This velocity is determined by the 
strength of electric field, the dielectric constant of and the viscosity of the medium, and by 
zeta potential. The light scattered at an angle of 17° is combined with the reference beam. 
This produces a fluctuating intensity signal where the rate of fluctuation is proportional to the 
speed of the particles. A digital signal processor is used to extract the characteristic 
frequencies in the scattered light (Malvern, 2005). 
The velocity of a particle in an electric field is commonly referred to as its electrophoretic 
mobility. The zeta potential may then be determined using the Henry Equation: 
 
 
2 ( )
3
zf ka
EU


  (3.2) 
Where: 
 z refers to zeta potential; UE is Electrophoretic mobility; ε is the dielectric constant; η is the 
viscosity; and ƒ(Ka) refers to Henrys function. 
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Figure 3.5 – The technique used to measure this velocity in Malvern’s Zetasizer Nano 
series(Malvern, 2005). 
 
 
3.4.4. Mean diameter and zeta potential measurements 
1 mL of each peptide-lipid samples was transferred to a 3 mL polystyrene disposable cuvette 
in order to determine the mean diameter of the nanoparticles. At least 5 measurements of each 
sample were considered to calculate the mean size (nm) average and respective standard 
deviation, in a Zetasizer Nano ZS equipment. 
The same equipment was used to determine the superficial charge density of the peptide-lipid 
samples, and 1mL of each was added to a 1 mL universal dip cell to measure -potential value 
(mV). 
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If polydispersity is lower than 0,10, z-average values are reliable. On the other hand, if 
polydispersity is much higher than 0,10, the  z-average is not trustworthy. Therefore, in these 
cases, the weighted mean size was calculated using the following formula: 
 
 
(Population Mean size Population %)
Weighted mean size 
100
 


 (3.3) 
 
 
3.5. Encapsulation Efficiency 
A) Separation of encapsulated/non encapsulated peptide fractions by Amicon 
Centrifugation 
To determine the encapsulation efficiency, it is necessary to separate liposomes from 
supernatant in order to quantify peptide amount in each of these two fractions. To do so, 
DODAC:MO (1:2) liposomes were centrifuged for 20 minutes, at 4500 g in 50 KDa amicons. 
Amicons are falcon-like tubes and were pre-washed with 5 mL of ultra-pure water on a 
centrifuge during 15 minutes at 4500g (4°C). These tubes have a filter unit that allows the 
separation of liposome-peptide complexes from the free peptide. The free peptide is so small 
that it is able to pass through the filter, and a peptide encapsulation fraction as well as a free 
peptide fraction can be obtained. After this, samples were frozen (-80°C) prior to 
lyophilization. 
B) Liposome disruption 
Triton-x (1%) was added to encapsulated fractions to disrupt liposomes, followed by vigorous 
vortexing in order to allow a quantification of encapsulated peptide. The lipid fraction was 
separated from the once encapsulated peptides after centrifugation during 20 minutes at 
4500g. Samples were frozen (-80°C) prior to lyophilization. After lyophilization, samples 
were ressuspended in a small volume before tricine gel separation, as described in the next 
section (section C). 
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C) Tricine–SDS-PAGE protocol and staining technique 
The protocol used in this step is commonly used to separate proteins in the mass range 1–100 
kDa (Schägger, 2006). It is the preferred electrophoretic system for the resolution of proteins 
smaller than 30 kDa. The peptide involved in this work is 2,4 kDa. The concentrations of 
acrylamide used in the gels are lower than in other electrophoretic systems. These lower 
concentrations facilitate electroblotting, which is particularly crucial for hydrophobic proteins. 
This protocol for Tricine–SDS-PAGE includes efficient methods for coomassie blue or silver 
staining. 
After protocol described in paragraphs A and B above, three fractions for each sample were 
obtained: free peptide fraction; encapsulated peptide fraction; lipid fraction. On a first 
experiment, after lyophilization these fractions were dissolved in 100 µL of water. It was then 
added 20 µL of β.mercaptoethanol and 15 µL of the total volume to each well. On a second 
experiment, these fractions were dissolved in 20 µL of urea buffer (8 M), for lipid fraction 
and free peptide fraction, and in 50 µL of urea buffer for encapsulated peptide fraction. It was 
then added 5 µL of β.mercaptoethanol to samples dissolved in 20 µL of urea and 10 µL 
β.mercaptoethanol were added to samples dissolved in 50 µL. After this, 35 µL of each 
sample were loaded in each well. Finally, gels were stained with comassie blue and with 
silver stain. 
 
3.6. Delivery of antigenic BCR-ABL junctional peptide 
Since this work aims to create an innovative system to treat chronic myeloid leukemia, 
combining lipid vesicles with a CML peptide, TNF-α quantification can be the proper 
approach to evaluate the system´s ability to stimulate an immune response. Tumor Necrosis 
Factor-alpha (TNF-α) is a pro-inflammatory cytokine that mediates several chronic 
inflammatory diseases. It is produced and secreted primarily by macrophages and monocytes 
in response to a bacterial inflammation or a tumor. The overproduction of TNF-α is strongly 
involved in acute inflammation and chronic inflammatory diseases as it plays an important 
role in host defense and immunosurveillance. 
Large amounts of TNF-α are released in response to lipopolysaccharide, LPS (Moreira-
Tabaka et al., 2012; Pérez-Pérez, Shepherd, Morrow, & Blaser, 1995). Thus, LPS was 
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primarily tested to prove that the dose used is capable of inducing TNF-α production and that 
THP-1 cells are responsive to this lipopolysaccharide. 
 
3.6.1. Cell Culture 
Human THP-1 cells, cell line derived from the peripheral blood of a patient with acute 
monocytic leukemia, were grown in RPMI1640 supplemented with 20% of FBS, 1% of an 
antibiotic/antimycotic solution and 1% of L-glutamine, with 5 % CO2 at 37 ºC. This 
monocytice cell type is characterized by suspension growth. This cell line is used as a model 
for mimicking the function and regulation of monocytes and macrophages (Qin, 2012). 
 
3.6.2. LPS Extraction assay 
LPS was extracted from E. coli HB101 strain grown for 24h at 37°C with stirring, in lysogeny 
broth (LB) medium. Then 50 mL of cells were collected in a stationary phase with an optical 
density (660 nm) of approximately 0.8. Cells were washed twice with PBS (1x) and 
resuspended in 1 mL of RPMI medium without FBS. After this, cells were incubated at 100°C 
for 10 minutes to disrupt cells and release LPS, and filtered with a 0.2 µm pore size filter. The 
filtrate fraction was applied to THP-1 cells. 
 
3.6.3. LPS Activation assay 
First, cells were centrifuged at 1100 rpm for 7 minutes (25°C). After obtaining the pellet, the 
supernatant was removed and 3mL of RPMI medium was added. To count cells a small 
volume was analyzed in Neubauer chamber. Then, each well of a 24-well culture plate was 
loaded with a volume of 500 µL of THP-1 cells culture at a density of 0.5x10
6
 cells/mL and 
100 µL of LPS at 0%, 25%, 50% and 100% were incubated with cells. Samples were 
collected to micro tubes and frozen after 4h, 12h and 24h of incubation. The response of 
stimulated THP-1 cells was assessed by determining the amount of TNF-α using an ELISA 
KIT for human TNF-α in a 96 well tissue culture plate. 
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3.6.4. Peptide and Peptide/DODAC:MO(1:2) Activation assay 
The same protocol described for LPS activation assay was used in this step. To understand if 
BCR_ABL peptide used in this work could stimulate the production of TNF-α, six peptide 
concentrations dissolved in HEPES buffer were tested: 5, 10, 20, 50, 80 and 100 µg/mL. 
Samples were collected and frozen after 4h of incubation with cells, prior to TNF-α 
quantification with ELISA KIT. 
Peptide/DODAC:MO(1:2) complexes were prepared by method E and C, as mentioned in 
section 1.2.1.1. Initially, 5 mL of samples at 1/300 and 1/500 molar ratio were produced. 
Then, samples were centrifuged for 20 minutes, at 4500 g in 50 KDa amicons and free peptide 
fraction was separated from peptide encapsulated fraction. This separation resulted in a 
volume of 2.1 mL for each encapsulated fraction which means that peptide and lipid 
concentrations were increased. Then, the same protocol for LPS and peptide activation was 
used to test peptide/DODAC:MO(1:2) formulations. 
 
3.6.5. ELISA assay procedure 
The Enzyme-Linked Immuno Sorbent Assay (ELISA) is a specific and highly sensitive 
method for quantitative measurements of cytokines or other analytes in solutions. This assay 
is suitable for the quantification of soluble mediator TNF-α. ELISA kit for human TNF-α is 
easy to conduct and commonly used in laboratory. 
This assay is based on the use of a combination of two monoclonal coating antibodies, TNF3 
and TNF4. The first monoclonal antibody (mAb) is coated on a microplate and is able to 
capture the cytokine of interest. The second antibody is used for detection as it binds to a 
different epitope on the cytokine. This detection antibody is, in turn, labeled with biotin, 
which allows subsequent binding of a Streptavidin-conjugated enzyme. Any unbound 
reagents are washed away. When substrate is added, a color reaction will develop that is 
proportional to the amount of cytokine bound. The concentration of cytokine is determined by 
comparison with a standard curve with known concentrations of cytokine (“Mabtech,” 2013). 
Figure 3.6 illustrates the basic concept of the ELISA technique. 
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Figure 3.6 – The ELISA technique illustrated (“Mabtech,” 2013). 
 
 
3.6.5.1. Experimental work 
First, each microplate well is incubated with 100 µL of mAb TNF 3/4 overnight at 4-8°C. 
After washing with 200 µL of PBS twice, each well is incubated with 200 µL of incubation 
buffer (PBS (1x), 0.05% Tween and 0,1% BSA) for 1h at room temperature, after which wells 
are washed again five times with PBS containing 0.05% Tween. Then, 100 µL/well samples 
and TNF-α standards previously prepared are added and incubated for 2h at room 
temperature. After washing five times with incubation buffer, 100 µL of mAb biotin at 1 
µg/mL (in incubation buffer as well) were incubated for 1h at room temperature. After 
washing five times with incubation buffer again, 100 µL of Streptavidiv-ALP diluted 1:1000 
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in incubation buffer were incubated for 1h at room temperature. After washing five times with 
incubation buffer for the last time, 100 µL of pNPP substrate were added and optical density 
was measured (405 nm) in an ELISA reader after 15 minutes. 
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“The important thing in science is not so much to obtain new facts as to discover new ways of 
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 William Lawrence Bragg (1890 – 1971) 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
(Page intentionally left blank) 
Chapter 4  Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML 
54 Fátima Machado 
4. CHAPTER 4  RESULTS AND DISCUSSION 
 
With this work we pretend to find the best methodology to produce a nanoparticle 
(peptide/liposomes) with the best physic-chemical properties (ex: size, surface charge and 
encapsulation efficiency) in order to test its potential to be used as liposomal vaccine. 
DODAC:MO (1:2) liposomes were prepared using three different preparation methods: lipid 
film hydration (MLV), lipid film hydration/extrusion (SUV), ethanolic injection (MVV) and 
ethanolic injection/extrusion. 
The nanoparticles (peptide/liposome) were prepared using five different protocol (A, B, C, D, 
E): 
A – liposomes prepared by lipid film hydration (MLV) followed by peptide incubation; 
B – liposomes prepared by lipid film hydration (lipid/peptide); 
C – liposomes prepared by ethanolic injection (MVV) followed by peptide incubation;  
D – liposomes prepared by ethanolic injection (lipid/peptide); 
E – liposomes prepared by lipid film hydration/extrusion  followed by peptide incubation. 
Three different peptide concentration were studied, 10 µg/mL, 20 µg/mL and 40 µg/mL, and 
several total lipid concentration (0.35 mM, 0.7 mM, 1.05 mM, and 1.75 mM) were tested in 
order to get different peptide/lipid molar ratio (1/100, 1/200, 1/300, and 1/500). 
The physicochemical properties of peptide/DODAC:MO (1:2) complexes were thoroughly 
analyzed by DLS assays (mean size and zeta-potential). Since DODAC and MO molar ratio 
are kept constant, it is expectable that all modifications observed in particles structure will be 
caused by the changes on  peptide/lipid molar ratio due to the increase of lipid or peptide 
concentration and also preparation methodologies. 
Zeta potential and mean diameter are two structural parameters that enabled the 
physicochemical characterization of the final peptide/lipid nanoparticle, and further 
evaluation of its applicability as liposome vaccine. 
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The z-average value giving by the Zetasizer Nano ZS equipment was carefully considered in 
the samples where the polydispersity index was superior to 0.10. If polydispersity is lower 
than 0.10 z-average values are reliable. On the other hand, if polydispersity is much higher 
than 0.10 the z-average cannot be used and we should analyze the population’s distribution. 
The size distributions of the samples were analyzed individually and a new mean particle 
diameter was calculated through the weighted mean of the most representative size peaks of 
the samples. 
 
4.1. Effect of pH, peptide concentration and sonication  
Before studying the encapsulation efficiency of BCR-ABL peptide into the liposomes, the 
peptide behavior in buffer solutions at different pH was separately analyzed in terms of mean 
size and surface charge. These results may provide an insight of peptide structural 
conformation changes and its degree of aggregation in solution which may play an important 
role on peptide-liposomal membrane electrical attraction (Friede et al., 1993; Gregory 
Gregoriadis, 2007a; Ikonen, Murtomäki, & Kontturi, 2010; Strömstedt et al., 2010). Thus, this 
study emerges as an attempt to characterize and to know the most suitable pH condition to 
solubilize the peptide prior to liposome encapsulation. 
At this point we would like to know if this peptide could resist to sonication, and if this 
procedure could induce some level of peptide disaggregation. Therefore, peptide behavior 
after sonication was thought important to study. 
(A) pH effect  
Three different concentrations of peptide (10 µg/mL, 20 µg/mL, 40 µg/mL) were solubilized 
in a citrate-phosphate buffer at pH 4, 7.2 and 9. Figure 4.1 shows the weighted mean size and 
z-potential values for three different peptide concentrations at different pH condition, before 
and after sonication.  
 
 
Chapter 4  Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML 
56 Fátima Machado 
Figure 4.1 – Results of weighted mean size (nm) (bars - left axis) and z-potential (mV) 
(▬■▬ - right axis) for preparations of 10 µg/mL, 20 µg/mL and 40 µg/mL of BCR-ABL 
peptide, in citrate-phosphate buffer at pH=4, 7.2 and 9, before and after sonication. 
 
From Figure 4.1 we can observe that the peptide has a distinct behavior depending on pH 
conditions. Generally, before and after sonication the highest mean sizes were observed in 
acidic conditions, varying between 131.2 nm and 450 nm depending on the peptide 
concentration. On the contrary, the smaller mean sizes were noted in alkaline conditions 
(pH=9), varying from 50 nm and 244.3 nm At neutral conditions (pH=7.2) the mean sizes are 
more similar and not so concentration dependent varying from 199.1 nm to 268 nm. 
We can also observe that pH has also greater influence in the peptide surface charge. At 
pH=4, z-potential are the lowest being close to zero, while at pH=9 the peptide exhibited a 
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stronger negative charge. However, the highest z-potential values were observed at neutral 
pH. 
From Figure 4.1 we can note that sonication was responsible for changes in mean sizes and z-
potential at the three pH conditions, with the exception for the mean sizes at pH=7.2 that were 
not significantly changed. 
Before sonication 
(i) pH 7.2 
At neutral conditions, with increasing peptide concentration, an increase in z-potential was 
first observed followed by a decrease: -17.7 mV (10µg/mL), -21.2 (20µg/mL) and -17.5 mV 
(40µg/mL). 
The mean sizes of the three concentrations are similar: 251.3 nm (10µg/mL), 199.1 nm 
(20µg/mL), 268 nm (40µg/mL). Despite a decrease at 20µg/mL, mean sizes at neutral pH are 
not so concentration dependent. 
At neutral pH, as H
+
 ions and HO
-
 ions are in equilibrium, it is expected a negative surface 
charge (z-potential) due to the balance between the four negative amino acid residues (one 
aspartic acid and three glutamic acids) and the two positive ones (arginine and lysine) that 
make up the BCR-ABL peptide (Table 2.1). Moreover, as most proteins at physiological pH, 
this peptide ‘s amino acids are above their isoelectric points, which results in a net negative 
charge (Mangino & Harper, 2007). From Figure 4.1 we can confirm that the BCR-ABL 
peptide is, in fact, characterized by an overall negative surface charge. 
(ii) pH 4 
At pH=4, the peptide has a different behavior depending on peptide concentration. Figure 4.1 
shows that an increase in peptide concentration leads to an increase in negative surface 
charge: -1.6 mV (10 µg/mL), -6.1 mV ( 20 µg/mL) and -7.4 mV (40 µg/mL). Nevertheless, in 
acidic condition, the peptide showed the negative surface charge more close to zero. 
The weighted mean size follows the same trend as it increases with increasing peptide 
concentration: 131.2 nm  (10 µg/mL), 273.7 nm (20 µg/mL) and 328.6 nm (40 µg/mL). 
Generally, higher mean sizes were observed at pH=4 when compared to the neutral and 
alkaline conditions. This is in accordance to a reported study that reveals that an hydrophobic 
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peptide forms aggregates under acidic conditions (Do et al., 2013), which can explain the 
increase in mean size. 
The pKa and pI values of the BCR-ABL peptide´s amino acids (see section 2.2.2) explains 
that at lower pH the most (once negative) amino acids are more likely to have a surface 
charge close to zero while the positive ones remain positively charged. In fact, at pH=4, the 
pH is lowered far below the isoelectric point of most amino acids, the peptide will lose some 
negative charge and contain more positive charges which results in a net charge closer to zero. 
When pH is lowered far below the isoelectric point (pH=4), the peptide will lose its negative 
charge and contain more positive charges. The excess of H
+
 ions at acidic conditions, that 
neutralize negative amino acids, also play a role in the decrease of the surface charge 
observed at pH=4. 
Results may suggest that the peptide has been denatured. A common misconception is that 
since a peptide is a short protein, it is as unstable as protein but the truth is that a peptide is 
much more stable than a protein because, for example, due to their short length most peptides 
do not have tertiary structure which is unstable because it is held together by non-covalent 
bonds such as electrostatic interaction. So, a peptide can only be damaged by covalent 
modification or break of peptide bonds and the term “denaturation” cannot be applied in this 
case. Because the secondary structures peptides are stabilized by weak, non-covalent 
interactions, these structures are easily disrupted by agents that disrupt these interactions, 
including changes in pH, among other parameters, which may end in loss of function.  
Since the helices and sheets are held together by hydrogen bonds, any condition that may 
interfere with the formation of these bonds can disrupt and destroy the structure. High 
concentrations of H
+
 interfere with the formation of hydrogen bonds. Under these 
assumptions, results indicate that an acidic pH induces a change in the structure of the peptide 
resulting in a possible change of peptide activity. In fact, structural changes induced by 
denaturation under acidic conditions has been demonstrated by a number of techniques 
(López-Alonso et al., 2010). 
(iii) pH 9 
At alkaline conditions, the peptide has a different behavior depending on peptide 
concentration. An increase in peptide concentration leads to a decrease in negative surface 
charge: -11.4 mV (10 µg/mL), -10.2 mV (20 µg/mL) and -8.3 mV (40 µg/mL). 
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With increasing peptide concentration, the weighted mean size first suffers an increase 
followed by a decrease: 189.1 nm (10µg/mL), 244.3 nm (20µg/mL) and 101.7 nm (40µg/mL). 
At alkaline pH positive amino acids may still be positive but close to zero, while negative 
amino acids remain negative and are in higher number. At pH=9 HO
-
 ions neutralize some 
peptide positive charges, which also contribute to the increase in negative surface charge 
when compared to acidic conditions. 
The effects of high pH are analogous to those of low pH (Mangino & Harper, 2007) and can 
cause peptide damage.  However, at alkaline pH the peptide obtained a stronger negative 
charge when compared to acidic conditions. This may be partially explained by the fact that 
pH=9 is largely above most amino acids isoelectric point, contrary to what happens at pH=4. 
Furthermore, the difference between pH=7.2 and pH=4 is 3.2, while the difference between 
pH=7.2 and pH=9 is much lower, 1.8. Thus, despite both acidic and alkaline conditions 
induce a change in peptide structure that leads to the decrease of z-potential when compared 
to the neutral condition, this change is also observed at pH=9, although, in less extension. 
When pH is increased, at pH=9, mean sizes decreased when compared to neutral condition. In 
fact, it is visible the appearance of smaller populations (Appendix I), explaining the decrease 
in the weighted mean size. This suggests some level of disaggregation at this pH condition 
compared with the acidic and neutral conditions. Despite alkaline pH has a different effect in 
peptide mean sizes when compared to pH=4, a change in its structure is also suggested. 
Both z-potential and mean size results suggested that a neutral pH is the proper condition to 
solubilize the peptide, maintaining its secondary structure and function. With a strong 
negative z-potential at pH=7.2, this peptide is expected to be attracted to cationic liposomes 
successfully (Friede et al., 1993; Gregory Gregoriadis, 2007a; Ikonen et al., 2010; Strömstedt 
et al., 2010). The three peptide concentrations tested are suitable to be used in the liposome 
encapsulation study. 
After Sonication 
Sonication, or ultrasound, is often utilized to disperse the substances. Although sonication 
cannot destroy covalent bond, it can have a profound influence on weak chemical bonds such 
as hydrogen, hydrophobic and ion bonds. Generally, after 10 seconds of sonication the 
samples presented higher negative surface charge for all pH conditions, however the 
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sonication procedure had greater impact either in mean size or z-potential values at alkaline 
conditions. 
 (i) pH 7.2 
At neutral pH, z-potential values followed the same trend as before sonication, although they 
became more intense. With increasing peptide concentration, an increase in z-potential was 
first observed followed by a decrease: -13.1 mV (10 µg/mL), -27.5 mV (20 µg/mL) and -18.6 
mV (40 µg/mL). A peculiar high z-potential is observed for 20µg/mL before and after 
sonication as well. 
The mean sizes of the three concentrations generally increased when compared to mean sizes 
before sonication but the peptide concentration apparently did not induce significant changes 
as well: 229.5 nm (10 µg/mL), 306.9 nm (20 µg/mL), 294.1 nm  (40 µg/mL). Despite a 
smaller value at 10µg/mL, mean sizes at neutral pH are still not so concentration dependent 
when compared to pH=4 and 9. 
 (ii) pH 4 
At pH=4, after 10 seconds of sonication, mean sizes increased but followed the same trend as 
with increasing peptide concentration mean sizes increased: 186.4 nm (10 µg/mL), 331.4 nm 
(20 µg/mL) and 470.8 nm (40 µg/mL); similar to what was observed before sonication. 
A significant change was observed in z-potential. After sonication, generally the three z-
potential values increased and suffered an inversion, as it decreased with increasing peptide 
concentration this time: -9 mV (10 µg/mL), -9.3 mV (20 µg/mL) and -6.99 mV (40 µg/mL). 
 (iii) pH 9 
At alkaline pH (pH=9), the sonication procedure had greater impact either in mean size or z-
potential values. Mean sizes decreased and followed a different trend, while z-potential 
increased and followed a different trend as well. 
Peptide surface charge increased with increasing peptide concentration: -12.5 mV (10 
µg/mL), -14.5 mV (20 µg/mL) and -21.7 mV (40 µg/mL). While mean sizes first suffered an 
increase followed by a decrease: 53.7 nm (10 µg/mL), 175.1 nm (20 µg/mL), 153.2 nm  (40 
µg/mL). 
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An increase in negative charge after sonication suggests that negative amino acids are more 
exposed and, therefore, the peptide should be less aggregated. If peptides are dispersed rather 
than aggregated, its charge superficial density should be higher as well as its electrophoretic 
mobility, therefore, increasing the negativity of z-potential. However, the increase in most of 
the mean sizes after sonication is not in agreement with the disaggregation hypothesis. 
Somehow, sonication procedure is responsible for exposing more negative amino acids. 
Circular dichroism would be useful to confirm, or not, changes in peptide structure (Purdie, 
Brittain, Towell, & Manning, 1994). However, has been shown  that sonication procedure did 
not induce changes on a peptide’s secondary structure using the same technique  (Ruan, Luo, 
Zhang, & Xing, 2013). Nevertheless, results show a different peptide behavior before and 
after sonication. 
Furthermore, sonication is, apparently, responsible for decreasing PDI values (Silva et al., 
2008). The same was observed in this work for most of the samples while a few of them were 
kept constant (Appendix I). 
Different trends were observed with increasing peptide concentration at acidic and alkaline 
pH before and after sonication. However, this was not so evident at neutral pH where the 
peptide is suggested to be more stable, which lead us to believe that the peptide integrity is 
more ashored at neutral conditions. 
The behavior of different peptide concentrations vary from peptide to peptide, therefore, 
reported studies concerning this subject may be contradictory. Since information about this 
BCR-ABL peptide is hard to find, we present here, possibly, its first biophysical 
characterization under different pH conditions. 
B) Buffer effect 
Three different concentrations of peptide (10 µg/mL, 20 µg/mL, 40 µg/mL) were solubilized 
in a citrate-phosphate buffer and HEPES buffer at pH=7.2. Figure 4.2 shows z-potential and 
z-average results, before and after sonication. 
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Figure 4.2 – Results of weighted mean size (nm) (bars - left axis) and z-potential (mV) 
(▬■▬ - right axis) for preparations of 10 µg/mL, 20 µg/mL and 40 µg/mL of BCR-ABL 
peptide, in HEPES buffer and citrate-phosphate buffer at pH=7.2, before and after sonication. 
 
From Figure 4.2 we can observe that when peptide is dissolved in HEPES (pH=7.2) instead of 
citrate-phosphate buffer at the same pH conditions, the weighed mean sizes are much higher 
and present less negative surface charge (before and after sonication). A peculiar increase in 
negative surface charge is observed at 20 µg/mL of peptide concentration for both buffers 
(before and after sonication), suggesting a concentration dependent behavior. 
Citrate-phosphate buffer (150 mM KCl; 10 mM KH2PO4; 10 mM H3BO4 and 10 mM Na-
citrate) is composed of significantly more salts than HEPES (10 mM). Therefore, these results 
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indicate that an increase in the amount of salts induce a change in the structure of the peptide 
so that a decrease in particles mean size is achieved. This suggests that peptide particles are 
more disaggregated in citrate-phosphate buffer. Higher z-potential values may be due to a 
higher exposition of negative amino acids that resulted from the particle disaggregation. 
However, the possibility that citrate-phosphate may be unfolding the peptide secondary 
structure cannot be confirmed and should be considered. High ionic stregth that affect 
proteins and peptides may be achieved , among others, by high or low pH, but also by a high 
quantity of salts which can result in loss of function (Mangino & Harper, 2007). Electrostatic 
binding between peptides and liposomes may be salt sensitive as shown in other works 
(Colletier et al., 2002), which can affect the encapsulation efficiency of amphiphilic peptides, 
such as BCR-ABL peptide under study (Strömstedt et al., 2010). 
After sonication, mean sizes do not vary significantly, with the exception for 40µg/mL of 
peptide concentration in HEPES buffer that increased significantly. However, a decrease in z-
potential was observed for all peptide concentrations of both buffers. Apparently, sonication 
has influence on exposing more negative amino acids but a role on particle disaggregation 
cannot be confirmed. 
The PDI values decreased in a few samples but were kept constant for most of them. 
Appendix I show further information, a detailed size distribution. 
A peptide concentration of 10µg/mL was used in the subsequent work to obtain preliminary 
results about the most suitable lipid/peptide molar ratio and method of preparation. As peptide 
integrity was not accessed and particle disaggregation using sonication could not be 
confirmed, we decided to use a peptide solution without ultrasound treatment. 
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4.2. Incorporation of BCR_ABL peptide into DODAC:MO(1:2) 
liposomes 
4.2.1. Citrate-phosphate versus HEPES 
In a first attempt, peptide/liposomes nanoparticles were prepared in citrate-phosphate (pH=4, 
7.2 and 9) and HEPES (pH=7.2) buffer. Not for a particular reason, method C (liposomes 
prepared by ethanolic injection followed by peptide incubation) and a 1/500 peptide /lipid 
molar ratio were chosen to be tested in the first place. 
Figure 4.3 shows a photography of DODAC:MO(1:2) liposomes prepared by ethanolic 
injection in citrate-phosphate buffer at pH=9. 
 
Figure 4.3 – Photography of DODAC:MO(1:2) liposomes prepared by ethanolic injection in 
citrate-phosphate buffer at pH=9. 
 
Firstly, a volume of DODAC:MO was injected in a citrate-phosphate buffer solution (pH=9) 
but lipid precipitation was observed immediately (Figure 4.3), so incubation with a peptide 
citrate-phosphate solution was not necessary to be done. 
Secondly, when liposomes were prepared in HEPES buffer precipitation was not observed.  
After incubating these liposomes with a peptide HEPES solution, precipitation was not 
detected as well. 
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As the previous results indicated that citrate-phosphate buffer provides peptide particles with 
higher z-potential, as an alternative, we intended to prepare liposomes in HEPES buffer prior 
to incubation with a peptide citrate phosphate solution (pH=9). DODAC:MO precipitation 
was not noted after injecting this lipid in an HEPES solution, however, it was observed after 
incubating these liposomes with a peptide citrate-phosphate solution. Although in less 
extension, the sample appearance was similar to what is shown in figure 4.3. 
Lipid precipitation was also detected at pH=4 and 7.2 in citrate-phosphate, however, it was 
never observed when using HEPES (pH=7.2). As citrate-phosphate buffer contains 
significantly more salts than HEPES, this may explain the lipid precipitation. In fact, salts 
content is a critical issue and is responsible for inducing changes in liposomes (Gregory 
Gregoriadis, 2007b; Sabín, Prieto, Ruso, Hidalgo-Alvarez, & Sarmiento, 2006). The fact that 
a specific salt may be the cause for this can also be considered. However, further information 
about the interaction between DODAC and MO with the salts involved in this work is not 
available. 
HEPES buffer resulted to be more appropriate. On the contrary, citrate-phosphate buffer is not 
appropriate to prepare liposomes at any pH condition.  Taking in consideration that HEPES 
buffer mimics body fluids, such as human blood stream, and it is largely used in cell culture, 
due to the better performance on maintaining physiological pH despite changes in carbon 
dioxide concentration, this work was continued using HEPES buffer at a pH=7.2. 
Furthermore, HEPES has been used to prepare liposomes in a number of studies (Ikonen et 
al., 2010; Wattraint, Saadallah, Silva-Pires, Sonnet, & Sarazin, 2013; Xu, Costa, Khan, et al., 
2012), as well as to prepare specifically DODAC liposomes (Feitosa, Alves, Castanheira, & 
Oliveira, 2009). 
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4.2.2. Incubation time 
In order to know how much time it was necessary to incorporate the peptide in liposomes so 
that a stable nanoparticle could be achieved, a formulation of peptide/lipid molar ratio of 
1/500 was prepared by post-insertion protocols: method A, liposomes prepared by lipid film 
hydration (MLV) followed by peptide incubation, and method C, liposomes prepared by 
ethanolic injection (MVV) followed by peptide incubation. The mean sizes and z-potential 
were measured after 1 and 5 hours of peptide incubation at a concentration of 10µg/mL. 
Results for method A and C are presented in figure 4.4 and 4.5. 
 
Figure 4.4 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for lipid vesicles (control) and peptide/DODAC:MO 
nanoparticles prepared by method A at 1/500 molar ratio. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
Figure 4.4 shows that when nanoparticles are prepared by method A their weighted mean 
sizes decrease with increasing incubation time varying from 582.1nm to 271.1nm. 
Z-potential values after 1h of incubation suffers a slight increase (from +81.5 mV to 
+85.2mV) decreasing after 5h of incubation (from +85.2 mV to +75.2 mV). 
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These results suggest that first we must have an electrostatic interaction between the positive 
charge of the liposome and the negative charge of the peptide, and after 5h of incubation more 
positive charge of liposome may be neutralized, resulting in a nanoparticle of smaller size and 
lower surface charge. 
 
Figure 4.5 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for lipid vesicles (control) and peptide/DODAC:MO 
nanoparticles prepared by method C at 1/500 molar ratio. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
Figure 4.5 shows that when nanoparticles are prepared by method C their weighted mean 
sizes increases after 1h of incubation, decreasing after 5h. Through the size distributing 
profile we can observe that the ethanolic injection method produces a more heterogeneous 
population of nanoparticles and a higher mean size compared with the control. 
Z-potential values after 1h of incubation suffers a slight increase (+55 mV, +66.7 mV) 
decreasing after 5h of incubation (+55 mV, +55 mV).  
These results suggest that lipid film hydration (MLV) produce different nanoparticles in terms 
of size and zeta-potential when compared with ethanolic injection (MVV), and the peptide 
incubation time influences the organization of the final nanoparticle. Nevertheless, 1h of 
incubation was thought sufficient to continue the subsequent work of this thesis. Direct-
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insertion protocols, methods B and D, were not tested at this stage; however, samples 
prepared by these methods were chosen to be analyzed 1h after preparation as well as in the 
subsequent work. 
The study from this section provides an insight on how much time is necessary to achieve 
charge neutralization (electrostatic interaction between liposomes and peptides) within one 
peptide/lipid molar ratio, as the same incubation time will be used in all nanoparticles 
characterized in this thesis. A detailed study about the exact time of incubation in which the 
final nanoparticle is the most properly organized would be valuable in future works after 
choosing the proper peptide/lipid formulation. 
4.2.3. Effect of the preparation methods on nanoparticles behavior 
in solution 
Four methodologies were used to encapsulate peptide molecules at 10µg/mL concentration 
using four different peptide/lipid molar ratios: 1/100; 1/200; 1/300 and 1/500 and the final 
nanoparticles were analyzed by DLS assays 1h after preparation/incubation, before and after 
extrusion. 
(i) Lipid film hydration: Direct- insertion versus Post-insertion 
Figures 4.6 to 4.9 show z-potential (mV) and weighted mean diameter (nm) values for 
formulations prepared by post-insertion protocol, method A (lipid hydration/peptide 
incubation), and direct-insertion protocol, method B (lipid hydration with peptide solution), 
after extrusion. Results for nanoparticles before extrusion are presented in Appendix II. 
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Figure 4.6 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/100 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
Figure 4.6 shows that nanoparticles prepared by method A and method B presented a higher 
weighted mean size, 329.1 nm (A) and 227.1 nm (B), when comparing with the control, 
144.8nm. Z-potential followed the same trend, varying from +63.5 mV (A) to +61.6 mV (B) 
when comparing to +53.9 mV (LUV). 
Direct-insertion method (B) is responsible for producing nanoparticles with smaller mean 
sizes and lower z-potential when compared with nanoparticles prepared by post-insertion 
protocol (A), suggesting a different conformational organization of the peptide within the 
nanoparticle. 
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Figure 4.7 – At the left side are presented results of weighted mean size (nm) (bars -left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/200 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
Figure 4.7 shows that nanoparticles at 1/200 molar ratio present a higher weighted mean size, 
350 nm (post-insertion, A) and 292.7 nm (direct-insertion, B), when compared with LUV, 
136.6 nm.  
Z-potential presented some differences as well, varying from +63.4 mV (A) to +53.5 mV (B) 
comparing to +53.9 mV (LUV). It should be noted that nanoparticles prepared by direct 
insertion (B) show very similar z-potential values when comparing to the control. 
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Figure 4.8 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/300 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
First, it is important to note that the control shows a mean size of 325.3 nm while the 
respective population 1 (pk1) demonstrate that 96.6% of the particles in suspension have a 
mean size of 180.1 nm. This is the value that is going to be considered as it is more 
trustworthy. 
From figure 4.8 we can observe that nanoparticles at 1/300 molar ratio presented slightly 
higher mean sizes when compared to LUV, (180.1 nm), and direct-insertion method B 
produced nanoparticles with higher mean diameter (257.6 nm) than post-insertion method A 
(203.2 nm). 
Z-potential values of peptide/lipid nanoparticles prepared by method A and B (+54.7 mV and 
+54.3 mV, respectively) are slightly lower than z-potential values of LUV (+56 mV). 
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Figure 4.9 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/500 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
Results presented in Figure 4.9 show that lipid vesicles, LUV, have smaller mean sizes (135.2 
nm) than peptide/liposomes nanoparticles at 1/500 molar ratio. Nanoparticles mean sizes are 
smaller when produced by post-insertion (A), 160.7 nm when compared to direct-insertion 
(B), 173.5 nm. 
Z-potential followed the same trend as values are higher for nanoparticles, varying from 
+61.7 mV (A) to +68.1 mV (B), when compared to LUV (+54.1 mV). Post-insertion protocol 
(A) produced smaller nanoparticles than direct-insertion protocol (B). 
From figure 4.6 to 4.9 we can observe that the negative charge of the peptide backbone has 
been neutralized by the addition of DODAC:MO (1:2) cationic aggregates in all formulations, 
suggesting that peptides were attached/incorporated into liposomes by electrostatic interaction 
attraction (Friede et al., 1993; Gregory Gregoriadis, 2007a; Ikonen et al., 2010; Strömstedt et 
al., 2010). However, different particle organizations were achieved according to the method 
of preparation and to the lipid content used to achieve different peptide/lipid molar ratios, 
which is in agreement with the literature (Gregory Gregoriadis, 2007b). 
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All nanoparticles showed higher mean sizes than the respective LUV (control). Peptides 
attached to liposomes membrane have been shown to produce higher mean size particles 
(Silva et al., 2008; Wattraint et al., 2013). Moreover, increasing sizes may be caused by 
liposome fusion induced by the negatively charged peptides attached to lipid vesicles (de 
Souza, Frisch, Duportail, & Schuber, 2002; Pecheur, Martin, Ruysschaert, Bienvenue, & 
Hoekstra, 1998).  
Post-insertion protocol (A) seems to induce a greater change in LUV after peptide addition 
when compared to direct-insertion technique (B). At 1/300 and 1/500 molar ratio the higher 
lipid content was able to better organize the amount of peptide within the nanoparticles 
prepared by methods A and B as they produced more similar sizes. However, at 1/100 and 
1/200 method A produced considerably higher nanoparticles. This may support the hypothesis 
that post-insertion protocol produces nanoparticles with higher amount of peptide attached to 
the outside of liposomal membrane rather than inside or attached to the inner side, which 
would be suitable for the aim of this thesis. In fact, it is known that peptides attached to the 
surface of liposomes are capable of inducing a stronger response (Gregory Gregoriadis, 
2007a; Guan et al., 1998; Moreira, Ishida, Gaspar, & Allen, 2002; V. P. Torchilin, 
Rammohan, Weissig, & Levchenko, 2001). 
Increasing lipid content is a critical parameter when preparing nanoparticles. Results show 
that nanoparticles prepared by lipid film hydration at 1/100 and 1/200 molar ratios are similar, 
suggesting that an increase in lipid content from 0.35 mM to 0.7 mM has not a great impact in 
the final nanoparticles.  However, an increase from 0.7 mM (1/200 molar ratio) to 1.05 mM 
(1/300 molar ratio) leads to a considerable change. An increase in lipid concentration from 
1.05 mM to 1.75 mM leads to another reorganization of the final nanoparticle. 
In the distribution profiles from formulations 1/100 to 1/500, we can that the final 
nanoparticles become more homogeneous and compact. Generally, formulations with higher 
content of lipid, 1/300 (1.05 mM) and 1/500 (1.75 mM), showed more monodisperse 
populations and smaller sizes than 1/100 (0.35 mM) and 1/200 (0.7 mM) formulations. Higher 
lipid content produces considerably more lipid vesicles, thus, peptide particles per liposome 
should be significantly lower. In fact, a reported study presents a pore formation model 
induced by amphipathic peptides in liposomes that is based on the fact that when the vesicle 
size distribution is shifted towards smaller vesicles, there would be less of peptide molecules 
bound per liposome (Nir & Nieva, 2000). Thus, less negatively charged peptides attached to 
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each liposome induce less vesicle fusion, explaining the presence of smaller mean sizes at 
1/300 and 1/500 molar ratios.   
The results above suggest that an increase in lipid concentration leads to an increasingly better 
peptide-liposome organization, but also that there is a critical concentration below which there 
is too much peptide that cannot be properly incorporated (1.05 mM). Above this lipid 
concentration, an increase in mean size was observed for nanoparticles prepared by both 
methods A and B. In fact, 1 mM is the concentration at which DODAX vesicles have been 
typically produced ((Feitosa et al., 2009; Feitosa & Alves, 2008; Oliveira et al., 2012). 
Z-potential values are generally higher, particularly when post-insertion protocol (A) was 
applied. These results are consistent with other studies in which an increase in the final 
nanoparticles surface charge was achieved after attaching cationic liposomes to negatively 
charged peptides by lipid film hydration (Silva et al., 2008). When direct-insertion protocol 
(B) was applied, a similar effect was observed although in less extension. On one hand, 
nanoparticles prepared by method B showed higher z-potential at 1/100 and 1/500 molar 
ratios. On the other hand, at 1/200 and 1/300 z-potential values were very close to LUV, 
showing even a very slight decrease (Figure 4.7 and 4.8).  
Although both methods induced different conformational organizations, nanoparticles 
prepared by method B showed closer features to the control (LUV) when compared to method 
A. This reinforces that the post-insertion protocol has a strong influence in nanoparticle’s 
mean size. This influence may be related to a higher peptide attachment to the surface of 
liposomes that, after inducing liposomes fusion and increasing vesicles size, a different 
surface charge rearrangement is also achieved. Distinct surface charge rearrangements were 
also observed with increasing lipid concentration. 
(ii) Ethanolic injection: Direct- insertion versus Post-insertion 
Figures 4.10 to 4.13 show z-potential (mV) and weighted mean diameter (nm) values for 
formulations prepared by post-insertion protocol, method C (ethanolic injection/incubation), 
and direct-insertion protocol, method D (ethanolic injection), after extrusion. A peptide 
concentration of 10 µg/mL was tested. The results for the nanoparticles before extrusion are 
presented in Appendix II. 
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Figure 4.10 – At the left side are presented results of weighted mean size (nm) (bars - left 
axis) and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles 
prepared by method C and D at 1/100 molar ratio, after extrusion. At the right side are 
presented the distribution of intensity profiles of the respective mean size and z-potential. 
 
Figure 4.10 shows that weighted mean diameters are higher in nanoparticles at 1/100 molar 
ratio than in MVV. Peptide/lipid nanoparticles prepared by post-insertion (C) presented 
higher mean size , 260.9 nm,  than nanoparticles produced by direct-insertion (D), 184,7 nm. 
Z-potential follow the opposite tendency as nanoparticles prepared by method C and D have a 
lower surface charge (+50 mV and +53,7 mV, respectively) than the MVV control (+54.8 
mV). 
Nanoparticles prepared by method D are much more similar to the control than nanoparticles 
prepared by method C. 
 
0
10
20
30
40
50
60
70
80
90
100
0
50
100
150
200
250
300
350
400
Control
MVV
C
(post)
D
(direct)
Z
-p
o
te
n
ti
al
 (
m
V
) 
W
.M
. 
S
iz
e 
(n
m
) 
Method 
1/100 
Chapter 4  Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML 
76 Fátima Machado 
 
Figure 4.11 – At the left side are presented results of weighted mean size (nm) (bars - left 
axis) and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles 
prepared by method C and D at 1/200 molar ratio, after extrusion. At the right side are 
presented the distribution of intensity profiles of the respective mean size and z-potential. 
 
Figure 4.11 shows that weighted mean diameters of nanoparticles at 1/200 molar ratio 
prepared by post-insertion (C) and direct-insertion (D) are slightly higher compared to the 
control  (MVV), and peptide/lipid nanoparticles prepared by method C (197 nm) have slightly  
higher mean sizes than nanoparticles produced by method D (174.3 nm).  
Nanoparticles prepared by method C presented Z-potential values are slightly higher in (+60.1 
mV) compared to nanoparticles prepared by method D (+57 mV) and also to the control 
(+57.1  mV). Post-insertion technique produced higher mean diameters than direct-insertion. 
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Figure 4.12 – At the left side are presented results of weighted mean size (nm) (bars - left 
axis) and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles 
prepared by method C and D at 1/300 molar ratio, after extrusion. At the right side are 
presented the distribution of intensity profiles of the respective mean size and z-potential. 
 
First, it is important to note that the control shows a mean size of 222.2 nm while the 
respective population 1 (pk1) demonstrates that 97.4% of the particles in suspension have a 
mean size of 164.7 nm. This is the value that is going to be considered for the control (MVV) 
as it is more trustworthy. A high PDI lead to a misleading mean size and it should be noted 
that the same happened in the control (LUV) prepared with the same lipid concentration, 1.05 
mM (Figure 4.8). 
Results presented in Figure 4.12 for 1/300 molar ratio show that control (MVV) have smaller 
mean sizes (164.7 nm) than peptide/liposomes nanoparticles. Method C produced slightly 
bigger nanoparticles (178.5 nm) than method D (174.3 nm). 
Nanoparticles Z-potential followed the same tendency. The nanoparticles prepared by 
methods C and D are slightly less charged (+46.6 mV and +42.7 mV, respectively) than the 
control (+49.8 mV). 
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Figure 4.13 – At the left side are presented results of weighted mean size (nm) (bars - left 
axis) and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles 
prepared by method C and D at 1/500 molar ratio, after extrusion. At the right side are 
presented the distribution of intensity profiles of the respective mean size and z-potential. 
 
From results showed in Figure 4.13 for 1/500 molar ratio we can observe that MVV have 
smaller mean diameters than peptide/liposomes nanoparticles. However, from distribution by 
intensity profiles we can observe that PDI is high and pk1 comprises 100% of the populations. 
So, in this case, method C produces smaller nanoparticles (175.4 nm) than method D (MVV 
with 197.3 nm) considering both mean size and pk1. 
The nanoparticles prepared by methods C and D presented slightly higher Z-potential values  
(+57 mV and +64.4 mV, respectively) compared with the control (MVV) (+55.8 mV). The 
nanoparticles prepared by method D presented the higher surface charge.  
Results from figures to 4.10 to 4.13 suggest that peptides were incorporated into liposomes by 
electrostatic attraction using the ethanolic injection method, and the distinct methodologies 
adopted as well as the four peptide/lipid molar ratios produce different nanoparticles, similar 
to what happened with lipid film hydration method. 
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Generally, nanoparticles prepared by method C showed higher mean sizes than method D, 
with the exception for 1/500 formulation in which a slight smaller mean size was achieved. Z-
potential followed the opposite trend as it is lower for method C. 
Post-insertion protocol (C) apparently induces a greater change in MVV after peptide addition 
when compared to direct-insertion technique (D), an effect that is clearer at 1/100 and 1/200 
molar ratios.  This reinforces the hypothesis that post-insertion protocol produces 
nanoparticles with higher amount of peptide attached to the outside of liposomal membrane, 
inducing liposomes fusion and consequently creating higher nanoparticles.  
The results above show that nanoparticles prepared by lipid film hydration at 1/100 and 1/200 
molar ratios are similar, suggesting that an increase in lipid content from 0.35 mM to 0.7 mM 
has not a great impact in the final nanoparticles.  However, an increase from 0.7 mM (1/200 
molar ratio) to 1.05 mM (1/300 molar ratio) leads to a considerable change. An increase in 
lipid concentration from 1.05 mM to 1.75 mM leads to another reorganization of the final 
nanoparticle 
At 1/300 and 1/500 molar ratios, considerable changes were observed in the final 
nanoparticles indicating a lipid concentration dependent effect. Higher lipid content was able 
to better organize the amount of peptide within the nanoparticles prepared by methods C and 
D and they produced more similar sizes between each other and comparing to the control. As 
a similar behavior was observed for lipid hydration methods, this reinforces that an increase in 
lipid concentration leads to a more proper peptide distribution through the lipid vesicles and 
that there is a critical lipid concentration, 1.05 mM. Above this lipid concentration, an 
increase in mean size was observed for nanoparticles prepared by both methods C and D, 
while the opposite was observed for methods A and B. 
 
A) Lipid film hydration versus ethanolic injection 
The four distinct protocols, as well as the four different peptide/lipid molar ratios, used in this 
study lead to the production of different nanoparticles in terms of its conformational 
organization. While lipid film hydration is a mechanical dispersion method, ethanol injection 
is a solvent dispersion method. 
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While weighted mean diameters of nanoparticles prepared ethanolic injection methods, C and 
D, vary from 174.3 nm to 260.9 nm and PDI values vary from 0.161 to 0.250, nanoparticles 
prepared by lipid hydration methods, A and B, have higher mean sizes varying from 160.7 nm 
to 350 nm and smaller PDI that vary from 0.083 to 0.231. If we consider LUV and MVV 
preparations (controls), the same is observed for PDI values, but the opposite is observed for 
mean sizes as ethanolic injection produced higher mean size vesicles (175.1 nm; 171.9 nm; 
164.7 nm (pK1); 197.3 nm (pK1)) than lipid film hydration (144.4 nm; 136.6 nm; 180.1 nm 
(pK1); 135.2 nm). Therefore, ethanolic injection is characterized by the production of more 
heterogeneous vesicles with a higher mean size when compared to lipid film hydration that 
produces more homogeneous populations and smaller mean sizes. When a negatively charged 
peptide is added to the preparations, mean sizes tendency is inverted. 
Nanoparticles are more positively charged when prepared by lipid film hydration, varying 
from +55.3 mV to +85.2 mV, while ethanolic injection produce less positive particles, 
varying from +45.5 mV to +77.1 mV. This can be explained by the fact that nanoparticles 
prepared by ethanolic injection (MVV) followed by extrusion process are still MVV, although 
with less vesicles enclosured. 
If all the particles in suspension have a large negative or positive z-potential then electrostatic 
repulsion between molecules will overlap Van der Walls interactions. Consequently, 
molecules will tend to repel each other and there is no tendency to flocculate – increasing 
stability. On the other hand, when zeta potential values are close to neutrality, the opposite 
happens and prominent Van der Walls interactions cause molecules aggregation as there is no 
force to prevent the particles coming together and flocculating. Particles with zeta potentials 
more positive than +30 mV or more negative than -30 mV are normally considered stable 
(“Zeta Potential theory,” 2004). Thus, all nanoparticles presented in figures 4.6 to 4.13 can be 
considered as stable, and differences between them should be attributed to the method of 
preparation and lipid concentration. 
 
B) Post-insertion versus direct-insertion 
Despite mean size and PDI differences, a similar behavior was observed for post-insertion 
protocols (A and C) using lipid film hydration and ethanolic injection methods with 
increasing lipid concentration. Likewise, direct-insertion protocols (B and D) showed 
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similarities in the behavior of nanoparticles prepared by those two methods. The same 
correlation may be extended to z-potential, excepting for 1/100 formulation. 
As mentioned, results suggested that post-insertion protocols (A and C) produced 
nanoparticles with higher amount of peptides in the surface of liposomes. However, this 
outcome is stronger in nanoparticles prepared by lipid film hydration (A) rather than ethanolic 
injection. This is more evident at 1/100 and 1/200 molar ratios since nanoparticles prepared 
by method A showed mean sizes of 329.1 nm and 227.1, respectively ( Figures 4.6 and 4.7), 
while  nanoparticles prepared by method C showed mean sizes of 260.9 nm and 197.9 nm 
(Figures 4.10 and 4.11). The smaller size of peptide/lipid nanoparticles prepared by ethanolic 
injection can be caused by less peptide attached to the surface due to the morphological 
characteristics of vesicles produced by this method. 
 
C) Extrusion versus non-extrusion methodology  
It is important to refer that, previously, the extrusion process was undertaken with a filter of 
400 nm pore size. However, results showed high PDI even after extrusion (data not shown). 
Studies already reported that DODAC naturally forms vesicles with mean sizes around 247 
nm (Feitosa, Karlsson, & Edwards, 2006). Thus, a 200 nm pore size membrane was used 
instead. Using this pore size allows the production of the largest DODAC:MO(1:2) vesicles 
possible with low PDI, and higher mean size vesicles are more likely to be seen by the 
immune system. Furthermore, 200 nm vesicles have already been shown to be suitable for the 
immunological purpose of this thesis (V. P. Torchilin et al., 2001). Usually the optimal 
liposome size for administration is between 100 and 300 nm, because this size range of 
liposomes gives uniform and predictable drug-release rate and stability in the bloodstream 
(Gregory Gregoriadis, 2007b). 
Unprocessed liposomes (e.g.: without extrusion) have limited uses in research because of their 
large diameters, size heterogeneity, multi internal compartments, low-trap volumes, and 
inconsistencies from preparation to preparation (Gregory Gregoriadis, 2007b). For example, 
approximately 10% of the total lipid in a typical MLV preparation is present in the outer 
monolayer of the external bilayer (Hope, Bally, Webb, & Cullis, 1985). When a single bilayer 
encloses an aqueous space to form a vesicle with a sufficiently large radius that approximately 
50% of the total membrane lipids are present in the outer monolayer, a typical definition of a 
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LUV (Gregory Gregoriadis, 2007b). In fact, vesicles that did not undergo the extrusion 
treatment have rather polydisperse size distribution (Lasic, 1993) as we observed in this work 
(Appendix II). 
By comparing results before extrusion with results after extrusion, it is clear that the extrusion 
procedure has great influence in the final nanoparticle. Mean sizes became more 
homogeneous and Z-potential values decreased, possibly due to the normal loss of lipid (Xu, 
Costa, Khan, et al., 2012). In lipid film hydration methods, A and B, nanoparticle’s z-
potential before extrusion varies from + 55.3 mV to +85.7 mV and after extrusion these 
values decreased varying from +53.5 mV to +68.1 mV. In ethanolic injection methods, C and 
D, z-potential vary from +45.5 mV to +77.1 mV before extrusion and vary from +42.7 mV to 
+64.6 mV after extrusion. 
The extrusion process has more influence in decreasing z-potential and PDI of nanoparticles 
prepared by ethanolic injection, than in nanoparticles prepared by lipid film hydration. Yet, 
nanoparticles prepared by ethanolic injection have higher PDI before and after extrusion when 
compared to nanoparticles prepared by lipid film hydration. This may be explained by the 
morphological differences between MLV and MVV schematized in figure 2.3 (see section 
2.1.2). The size distribution in a MVV preparation produced by ethanolic injection is more 
heterogeneous than is in MLV. Each MVV can form and enclosure a very wide range of 
liposomes sizes. When MVV particles pass through the extrusion filter, those enclosured 
vesicles are released, explaining the higher PDI even after extrusion. Extrusion effect will be 
further analysed in the next section of results (4.1.4). 
 
D) Best methodology and formulation 
Nanoparticles prepared by post-insertion technique, lipid film hydration (A) and ethanolic 
injection (C), suggested that peptides can be attached to the surface of liposomes by taking 
advantage of electrostatic attraction between particles of opposite charge. The amphiphilic 
character of the BCR-ABL peptide comprised of 48% of hydrophobic amino acids has also 
influence on the success of peptide incorporation into liposomes. They can be easily 
incorporated into liposomes noncovalently due to their lipid-like amphipathic properties with 
minimized activity loss or without laborious chemical functionalization steps (Sardan, Kilinc, 
Genc, Tekinay, & Guler, 2013). 
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Lipid film hydration has been recognized as one of the best methodologies to achieve higher 
rates of encapsulation (Frézard, 1999; Kirby & Gregoriadis, 1984). In the same line of works, 
a higher lipid content is associated with higher encapsulation efficiency (Xu, Costa, Khan, et 
al., 2012). 
Until now method A is presented as the most encouraging nanoparticle preparation 
methodology as well as 1/300 and 1/500 peptide/lipid molar ratios, for the purpose of this 
thesis. However, as the extrusion process has been shown to be responsible for decreasing 
encapsulation due to peptide losses (Bhardwaj & Burgess, 2010; Colletier et al., 2002),  it was 
though be benefic to this work a more detailed analyzes of the influence of the extrusion 
process in the final nanoparticle and adopt a strategy to avoid those losses. 
 
4.2.4. Effect of MLV liposomes and LUV liposomes in the final 
nanoparticle – Method A versus method E 
(i) Incorporation of 10 µg/mL peptide concentration 
Formulations using 1/300 and 1/500 molar ratio showed the most encouraging results and 
will, therefore, be used in the subsequent work of encapsulation efficiency. An increase in 
lipid content induced more monodisperse nanoparticles. 
At this stage, the work was focused on the comparison between two methods: 
A - liposomes prepared by lipid film hydration (MLV) followed by peptide incubation and 
extrusion; 
E - liposomes prepared by lipid film hydration/extrusion (LUV) followed by incubation with 
peptide. 
As the lipid film hydration methods demonstrates more monodisperse populations than 
ethanolic injection methods, and as incubating peptide particles after lipid vesicle formation 
probably creates peptide/lipid complexes with more peptide particles attached to the outer 
membrane of liposomes rather than inside, method A was chosen to continue this work.  
Hereupon, it was important to understand which effect has on the final nanoparticles adding 
the peptide molecules to MLV suspension (before extrusion) or to LUV suspension (after 
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extrusion). Therefore, method E was added to this work. In method A, peptide particles were 
incubated with DODAC:MO(1:2) multi-lamellar vesicles (MLV). In method E, peptide 
particles were incubated with DODAC:MO(1:2) large uni-lamellar vesicles (LUV). 
Mean size and z-potential parameters were measured for methods A and E. Results are 
presented in figures 4.14 and 4.15. MVL and LUV control samples are presented as well. A 
peptide concentration of 10µg/mL and four peptide/lipid molar ratios were studied: 1/100; 
1/200; 1/300 and 1/500. 
 
 
Figure 4.14 – At the left side are presented results of weighted mean size (nm) (bars - left 
axis) and z-potential (mV) (▬■▬ - right axis) for nanoparticles prepared by method A and E 
at 1/100 (up) and 1/200 (bottom) molar ratio. At the right side are presented the distribution of 
intensity profiles of the respective mean size and z-potential. 
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From figure 4.14 we can observe that mean size values for 1/100 and 1/200 molar ratios 
follow the same tendency. Peptide/DODAC:MO nanoparticles prepared by method A 
presented higher mean sizes than LUV and slightly higher than MLV while nanoparticles 
prepared by method E presented higher mean sizes than LUV.  
Peptide/lipid nanoparticles produced by method E showed smaller mean sizes than 
nanoparticles prepared by method A. When lipid concentration was increased from 0,35mM 
(1/100) to 0,7mM (1/200), nanoparticles produced by both methods showed an increase in 
mean sizes as well. 
Z-potential values also follow the same trend for 1/100 and 1/200 molar ratios. MLV showed 
higher z-potential than nanoparticles prepared by method A. These, in turn, showed a higher 
surface charge than LUV. LUV presented higher surface charge than nanoparticles produced 
by method E. 
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Figure 4.15 – At the left side are presented results of weighted mean size (nm) (bars - left 
axis) and z-potential (mV) (▬■▬ - right axis) for nanoparticles prepared by method A and E 
at 1/300 (up) and 1/500 (bottom) molar ratio. At the right side are presented the distribution of 
intensity profiles of the respective mean size and z-potential. 
 
Figure 4.15 shows that at 1/300 molar ratio, nanoparticles prepared by method A and E have 
smaller mean sizes than the control (LUV). Nanoparticles prepared by method E showed 
slightly higher mean diameter than nanoparticles prepared by method A. Nanoparticles 
prepared by methods A and E, presented lower Z-potential  when compared with the control 
(LUV). Also nanoparticles prepared by method E showed lower z-potential than nanoparticles 
prepared by method A. 
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From figure 4.15 we can also observe that at 1/500 molar ratio, nanoparticles prepared by 
method A and E have higher mean sizes than LUV, and nanoparticles prepared by method E 
showed higher mean diameter than the one prepared by method A. In terms of surface charge, 
nanoparticles prepared by method E, present lower Z-potential compared to the control 
(LUV), while peptide/lipid particles prepared by method A showed higher z-potential than the 
control (LUV) and the nanoparticles prepared by method E. 
Generally, nanoparticles prepared by method A and E presented different mean sizes and z-
potential compared to the control (LUV). These results indicate that peptide particles are 
attached or incorporated into liposomes, producing different conformational organizations 
with nanoparticles with higher mean sizes and inducing a change in the surface charge of the 
nanoparticles.  
When analyzing the distribution profiles we can observe that at 1/100, 1/200 and 1/300 molar 
ratio, nanoparticles prepared by method E show the presence of nanoparticles with negative z-
potential this not being detected for nanoparticles prepared by method A. This may explain, 
partially, the smaller z-potential final values presented for nanoparticles produced by method 
E. The absent of negative particles may be due to loss of some peptide weakly linked to 
liposomes during extrusion in method A. Another possibility to take into consideration is that 
when the peptide-liposome conjugates pass through extrusion filter particles are rearranged 
and, therefore, the hypothesis that more peptide molecules may be hidden inside of the 
liposomes should be considered. In method E there are no peptide losses and they are not 
detached from liposomes membrane since the extrusion process is undertaken before peptide 
incubation. 
At 1/500 molar ratio, nanoparticles prepared by both methods, A and E do not show the 
presence of particles with negative surface charge. Differently to what happened for 1/100, 
1/200 and 1/300 molar ratios, at this 1/500 molar ratio nanoparticles produced by method E 
showed the absence of negative particles, indicating that the lipid content was enough to 
efficiently incorporate the peptides. 
Peptide/lipid nanoparticles prepared by method E showed lower z-potential than nanoparticles 
prepared by method A. However, when the lipid content is doubled from 0,35mM (1/100 
molar ratio) to 0,7mM (1/200 molar ratio), z-potential of nanoparticles prepared by method A 
is kept constant while z-potential of nanoparticles are prepared by method E increase. When 
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observing the distribution of intensity profiles of z-potential, nanoparticles prepared by 
method E (1/100 molar ratio) show the presence of some of more nanoparticle with negative 
surface charge, suggesting that a significant amount of peptide particles was not incorporated. 
A small lipid concentration (0,35mM) coupled to some lipid losses during the extrusion 
process, prior to peptide incubation, may lead to a critical total lipid content incapable of 
incorporating 10µg/mL of peptide concentration and achieving a stable final nanoparticle. 
Results showed that 1/100 and 1/200 molar ratios show many similarities. However, when the 
lipid content is raised different particles organizations are achieved at 1/300 and 1/500 molar 
ratios. In fact, increasing lipid concentration leads to more stable nanoparticles and the 
formulation using 1,75mM (1/500 molar ratio) of lipid content showed the most promising 
results. When peptide particles are incubated with previously extruded liposomes (method E), 
nanoparticles conformal organizations are different from the nanoparticles in which peptide is 
added to cationic liposomes followed by extrusion of the overall nanoparticle (method A). 
The addition of peptides to liposome after extrusion (method E) is apparently the suitable 
choice to produce nanoparticles with less antigen losses and with higher amount of peptide 
particles at the surface of the membrane of lipid vesicles.  
Therefore, this method was chosen to continue the subsequent work instead of method A in 
which the final nanoparticles organization is influenced by peptide losses (Xu, Costa, Khan, et 
al., 2012). 
The formulation consisting of 1/500 molar ratio prepared by method E showed encouraging 
results and the fact that it has the higher content of lipid, this opens the possibility of 
encapsulating a higher peptide concentration in future works (Xu, Costa, Khan, et al., 2012). 
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(ii) Incorporation of 10 µg/mol and 20 µg/mol peptide concentration 
Nanoparticles were prepared by method E (liposomes prepared by lipid film 
hydration/extrusion (LUV) followed by incubation with peptide) using two distinct peptide 
concentrations, 10 µg/mL and 20 µg/mL, and one lipid concentration, 1.75 mM. Two 
peptide/lipid molar ratio were tested, 1/250 and 1/500. 
Figure 4.16 presents the distribution of intensity profiles of mean size and z-potential for 
nanoparticles prepared at different peptide/lipid molar ratio. 
 
Figure 4.16 – Distribution of intensity profiles of the respective mean size (nm) and z-
potential (mV) for peptide/DODAC:MO nanoparticles prepared by method E at 1/500 (left) 
and 1/250 (right) molar ratio. 
 
From Figure 4.16 we can observe that nanoparticles prepared with 1,75 mM of lipid content 
and (1/500 molar ratio) present a mean size of 257 nm and a z-potential of +43.1 mV. When 
peptide concentration was increased to 20 µg/mL (1/250 molar ratio), nanoparticles mean size 
decreased to 209.9 nm and z-potential increased to +49.8 mV. Despite these differences, both 
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samples show very stable and homogeneous nanoparticles. Nevertheless, an increase in 
peptide concentration, apparently, leads to a more compact organization of the nanoparticle. 
It should be noted that a peculiar high z-potential was observed for 20 µg/mL at pH=7.2 in 
HEPES (see section  4.1.1- Effect of pH, peptide concentration and sonication). With a 
stronger negative charge, the peptide at this concentration would be attracted to the cationic 
liposomal membrane in a stronger manner compared to 10 µg/mL. 
After the previous results had demonstrated that the lipid content is detrimental in 
nanoparticles preparation, these results show that peptide content is also responsible for 
changes in the final nanoparticle features (Wattraint et al., 2013). In fact, vesicles aggregation 
can be achieved by increasing lipid concentration (Rapaport, Peled, Nir, & Shai, 1996), 
choosing larger peptides and also by increasing peptides concentration (Nieva, Nir, & 
Wilschut, 2008). In this work, the opposite was observed for one of these aspects as a 20 
µg/mL induced a smaller mean size than 10 µg/mL. Microscopic observations have revealed 
that fusogenic peptides induce liposome shrinkage prior to membrane fusion, therefore, this 
may be an explanation for the occurred. These results indicated that the liposome membrane 
shrank slightly during the fusion, whereas the total volume increased slightly (Nomura et al., 
2004). In any case, this may be understood as higher peptide concentrations may be 
encapsulated in 1.75 mM of total lipid content, opening the possibility of a detailed study in 
this subject. 
 
4.3. Encapsulation efficiency 
Choosing a peptide quantification assay was complicated by two factors: (i) the lack of 
information on how to efficiently separate the free peptide fraction from the encapsulated 
fraction; (ii) the lack of available assays capable of detecting such a low peptide 
concentration. 
The methodology used in this work, therefore, serves as a new attempt to quantify low 
peptide concentrations as well as to know if the methodology used to separate 
peptide/liposome fraction from free peptide fraction was successful. 
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Encapsulation efficiency was studied using tricine-SDS-PAGE protocol as it is a suitable 
electrophoretic system for the resolution of proteins smaller than 30 kDa (Schägger, 2006). 
Considering a peptide concentration of 1 0µg/mL, encapsulation efficiency was tested in the 
following samples: 
► 1/300 peptide/lipid molar ratio prepared by method E; 
► 1/500 peptide/lipid molar ratio prepared by method E; 
► 1/300 peptide/lipid molar ratio prepared by method C; 
► 1/500 peptide/lipid molar ratio prepared by method C. 
In method E, liposomes are prepared by lipid film hydration/extrusion (LUV) followed by 
incubation with peptide. In method C liposomes are prepared by ethanolic injection followed 
by peptide incubation. These samples were chosen as both methods and both peptide/lipid 
molar ratios presented encouraging results, allowing the comparison between lipid film 
hydration and ethanolic injection methods, as well as a comparison between two different 
lipid contents. 
Samples were produced in triplicate so that the same experiment could be optimized. 
 
► First Experiment 
Lyophilization was used to concentrate samples, expecting that peptide quantification would 
be better succeeded. After lyophilization and prior to gel analyses, samples were 
photographed. Figure 4.17 shows photographs of sample tubes from the first and second 
experiments. The third experiment presented similar results (not shown). 
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Figure 4.17 – Photography of sample tubes after lyophilization, containing: free peptide 
fraction (1) and peptide encapsulated fraction in which it lipid was not separated from peptide 
(2) – first experiment; free peptide fraction (3) and peptide encapsulated fraction after 
separation from lipid (4) – second experiment. 
 
From Figure 4.17 we can distinguish some differences between samples. Free peptide was 
observed for all formulations (Figure 4.17 - 1 and 3). Yet, the encapsulated fractions 
presented higher peptide quantities (Figure 4.17 - 2 and 4). 
Apparently, 1/500 formulation was able to enclosure slightly more peptide than 1/300 
formulation in each method (Figure 4.17 - 4). However, despite smaller lipid content, 1/300 
(method E) formulation was apparently able to encapsulate more peptide than 1/500 (method 
C) formulation. Samples prepared by lipid film hydration/extrusion, method E, demonstrated 
higher amount of encapsulated peptide than samples prepared by ethanolic injection, method 
C. 
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Firstly, coomassie blue staining was used to stain the gel but it was not sufficient to detect 
anything (not shown). Thus, silver staining was used afterwards, since it has a lower detection 
limit (Figure 4.18 and 4.19). Coomassie blue staining method allows the quantification of 
encapsulated peptide, yet, silver staining does not. 
Figure 4.18 shows gels stained with silver. In this figure are presented free peptide fractions 
(1-4) and peptide encapsulated fractions (5-8). As the peptide used in this work has 2,4 KDa, 
the location of the band corresponding to 2 KDa is represented. 
 
 
Figure 4.18 – Gel stained with silver staining. Samples showed correspond to method E and 
method C and to peptide/lipid molar ratios of 1/300 and 1/500. 
 
Figure 4.18 shows the presence of free peptide in the samples 2 and 4, corresponding to 1/300 
and 1/500 formulations prepared by method E. Free peptide was not detected in either 
formulations prepared by method C. Samples 5 to 8 correspond to the encapsulated fraction in 
which lipid was not separated from the peptide. These samples produced a smear effect 
probably due to the lipid molecules, and encapsulated peptide was not detected. 
All peptide/lipid nanoparticles were prepared in 5 mL with a peptide concentration of 
10µg/mL. Thus, all samples included a total 50 µg of peptide before separation of free 
fraction and encapsulated fraction. A standard sample consisting of 45 µg of peptide was used 
Chapter 4  Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML 
94 Fátima Machado 
as a control, the equivalent to 95% of encapsulation. Despite small quantities of free peptide 
being detected, in the standard sample it was not detectable any presence of it. This suggests 
that these results are not precise. Moreover, the 2KDa corresponding band does not appear in 
the gel, which indicates that the peptide did not run enough in the gel matrix, and reinforces 
that these results must be further confirmed. 
 
► Second Experiment 
Since results from the first experiment were not satisfactory, a second experiment with the 
same conditions was conducted. However, this time the encapsulated fraction was separated 
from the lipid content and both were analyzed separately. 
Figure 4.19 shows gels stained with silver where it can be observed results from samples 
presented in photographs above (4.17 - 3 and 4). So, in this figure are presented free peptide 
fractions (wells 1 to 4), peptide encapsulated fractions previously separated from liposomes 
(wells 5 to 6) and, additionally, samples with the resulting lipid content (wells 9 to 11). 
 
Figure 4.19 – Gels stained with silver staining. Samples showed correspond to method E and 
method C and to peptide/lipid molar ratios of 1/300 and 1/500. 
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From Figure 4.19 (Gel 1) we can observe that samples 1 to 4 show the absence of free peptide 
in all peptide/DODAC:MO formulations. On the other hand, wells 5 to 8 demonstrated the 
presence of the encapsulated peptide, especially in well 8 that corresponds to 1/300 
formulation prepared by method E. A smear effect was not detected in gel 1. 
Gel 2 includes the lipid fractions and a smear effect can be seen in 9 to 11 wells. Peptide 
presence was not detected. Therefore, it can be assumed that lipid molecules are responsible 
for this effect and it may be considered that the encapsulated peptide was successfully 
separated from liposomes. 
In both gels depicted in Figure 4.19, the peptide was not detected in the standard sample as 
also shown in Figure 4.18. Results from both first and second experiments may be misleading 
probably due to two factors. Firstly, considering that each well can be loaded with only 15µL, 
peptide concentration may have not been high enough even considering that samples were 
dissolved in only 100µL of water prior to gel analyzes. Secondly, in small volumes of water is 
harder to solubilize this amphiphilic peptide. In fact, peptide precipitate was observed in the 
micro tubes. However, vigorous vortexing apparently dissolved it and the experience was 
continued. 
 
► Third Experiment 
In a third experiment, after lyophilization, samples were dissolved in smaller volumes (50 µL) 
to increase peptide concentration, and the solvent used was urea buffer (8 M) in an attempt to 
increase the solubility of this amphiphilic peptide. Urea serves as an intermediate between 
water molecules and peptide molecules, which facilitates its hydration. A different gel 
preparation system was used as it allows the preparation of gels with deeper wells. These 
wells have a loading capacity of 35µL of sample volume instead of 15µL as in the previous 
experiments. 
Figure 4.20 shows gels stained with coomassie blue staining. In this figure are presented free 
peptide fractions (wells 1 to 4), peptide encapsulated fractions previously separated from 
liposomes (wells 5 to 6) and, additionally, samples with the resulting lipid content (wells 9 to 
12). 
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Figure 4.20 – Gels with comassie blue staining. Samples showed are relative to method E and 
method C and to peptide/lipid molar ratios of 1/300 and 1/500. 
 
Gel 1 from Figure 4.20 shows a smear effect in wells 5 to 8, corresponding to peptide 
encapsulated fractions, probably due to the urea buffer salts or a too high peptide 
concentration. Because of this, peptide quantification was not possible. Although photographs 
from Figure 4.17 showed free peptide presence in all tubes, free peptide was detected only in 
the sample corresponding to 1/300 peptide/lipid molar ratio prepared by method E (well 2). 
Peptide may have not been pipetted properly into gel wells due to its low solubility, or this gel 
electrophoresis analyses is not sensitive enough to detect such small peptide quantities. 
In gel 2, samples corresponded only to lipid fractions, in which significant haul can be seen 
again and peptide cannot. 
Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML Chapter 4 
Fátima Machado   97 
Results from third experiment are more reliable than results from the first and second ones. 
Still, peptide low solubility and the low peptide concentration used in this work, 10 µg/mL, 
made peptide quantification by this method difficult. Nevertheless, peptide encapsulation was 
proven as free peptide was detected in much smaller quantities than encapsulated peptide. 
In conclusion, the higher lipid content of 1.75 mM corresponding to 1/500 peptide/lipid molar 
ratio showed the highest encapsulation. This is consistent with reported results that indicate 
that higher lipid concentration is responsible, in part, for higher encapsulation efficiency 
(Colletier et al., 2002; Xu, Costa, Khan, et al., 2012). This was attributed to the positive 
impact on the total internal volume of liposomes and total vesicles number, resulting in higher 
entrapment volume (Xu, Costa, & Burgess, 2012; Xu, Khan, & Burgess, 2011, 2012a, 2012b). 
It should be noted that 1/300 molar ratio prepared by method E showed higher encapsulation 
than the sample consisting of 1/500 molar ratio produced by method C. This reinforces that 
the lipid film hydration is a powerful method to achieve high encapsulation efficiencies 
(Frézard, 1999; Kirby & Gregoriadis, 1984). However, another variable should be considered, 
the extrusion process. In method E, the peptide is added to extruded MLV (LUV) while in 
method C the peptide is added to non-extruded MVV. As already mentioned, unprocessed 
liposomes have limited use due to heterogeneity. Before extrusion,  MLV  has 10% of the 
total lipid presented in the outer monolyer of the external bilayer, while after extrusion this 
value is raised to 50% (Gregory Gregoriadis, 2007b). The same explanation may serve for 
MVV and other unprocessed liposomes in general. 
Several methods are available to evaluate the percentage of encapsulation (Zaia, Zaia, & 
Lichting, 1998). However, peptide concentration used in this work is so small that it was 
difficult to find a method capable to detect it. Nevertheless, efforts were made to understand 
which sample encapsulated more peptide. 
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4.4. Delivery of antigenic BCR-ABL junctional peptide 
4.4.1. Optimization of the control LPS Activation  
To evaluate the system´s ability to stimulate an immune response an ELISA was conducted 
for the quantification of TNF-α. LPS was primarily tested to prove that THP-1 cells are 
responsive to this lipopolysaccharide and that activation translates into TNF-α production and 
secretion. 
The formulations tested at this stage of the work are the same that were used in encapsulation 
efficiency tests, presented in the previous section of results. 
Figure 4.21 shows the amount of TNF-α produced in pg/mL after incubating cells with four 
different LPS concentrations at three time points: 4h, 12h and 24h. The quantification assay 
was conducted at the final stage of the ELISA, 15 minutes after sample incubation with pNPP 
substrate. The optical density (405 nm) was measured on a suitable microplate reader and a 
calibration curve (Appendix III) was used to correlate O.D. measurements with TNF-α 
concentration (pg/mL). 
 
Figure 4.21 – Quantitative results for TNF-α (pg/mL) produced in response to 4h, 12h and 
24h of incubation with four LPS conditions: 0%, 25%, 50% and 100%. 
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From Figure 4.21 we can observe that THP-1 cells are responsive to LPS. A residual quantity 
of TNF-α is naturally produced by these cells as it can be verified by samples to which LPS 
was not added (0% LPS). After 4h of incubation with LPS at 25%, 50% and 100%, TNF-α 
production is at its maximum when comparing to 12h and 24h, with minor exceptions. Other 
reported results have shown TNF-α production by THP-1 cells after 4h of incubation with 
LPS (Moreira-Tabaka et al., 2012). Therefore, 4h of incubation was chosen for subsequent 
work.  
Although the maximum TNF-α concentration was induced by incubating cells with the 
highest amount of LPS, 100% (12h), standard deviations are generally high and increasing 
LPS dose does not necessarily lead to production of higher amounts of TNF-α. After 4h 
incubation, 25%, 50% and 100% of LPS conditions did not show significant differences as 
they led to detection of TNF-α concentrations of 850.3 pg/mL, 1060.2 pg/mL and 940.8 
pg/mL, respectively. 
After 24h of incubation TNF-α concentration decreased significantly in all conditions, with 
the exception for 50% LPS sample. This may be a sign of cells exhaustion or toxicity. 
 
4.4.2. Peptide Activation assay 
To ensure that BCR-ABL peptide used in this work can stimulate the production of TNF-α, 
six peptide concentrations dissolved in HEPES buffer were tested: 5, 10, 20, 50, 80 and 
100µg/mL. Samples were collected and frozen after 4h of incubation with cells, prior to  
TNF-α quantification. 
Figure 4.22 shows TNF-α concentration produced by THP-1 cells with increasing peptide 
concentrations, after 4h of incubation. Using an ELISA kit, the optical density (405nm) was 
measured after 15 minutes incubation with pNPP substrate and a calibration curve (Appendix 
III Figure 2) was used to convert O.D. measures in TNF-α concentration (pg/mL). 
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Figure 4.22 – Quantitative results for TNF-α (pg/mL) produced by THP-1 cells in response to 
4h of incubation with increasing peptide concentrations: 0 (cells control), 0 (HEPES control), 
5, 10, 20, 50, 80 and 100 µg/mL. 
 
Although the sample that contains only cells (control) demonstrated a high concentration of 
TNF-α, Figure 4.22 clearly shows an increasing TNF-α production with increasing peptide 
concentration. Cells control sample odd result may be due to culture medium interference as it 
did not happen in the other experiences. 
Cells were also incubated with HEPES buffer which also resulted in some TNF-α production. 
This sample demonstrated a result similar to the sample that was incubated with the lowest 
peptide concentration, 5 µg/mL. From 10 µg/mL upwards, BCR-ABL peptide is capable of 
inducing a concentration dependent overexpression of TNF-α. The overproduction of TNF-α 
is strongly involved in acute inflammation and chronic inflammatory diseases as it plays an 
important role in host defense and immunosurveillance. 
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4.4.3. Peptide/DODAC:MO(1:2) Activation assay 
To evaluate if DODAC:MO (1:2) system can stimulate the production of TNF-α, 
peptide/DODAC:MO(1:2) nanoparticles prepared by method E (liposomes prepared by lipid 
film hydration/extrusion (LUV) followed by incubation with peptide) and C (liposomes 
prepared by ethanolic injection followed by peptide incubation) were tested: 
► 10µg/mL [peptido] and 1.75 mM [lipid] (1/500 molar ratio) -  method E 
► 10µg/mL [peptido] and 1.05 mM [lipid] (1/300 molar ratio) -  method E 
► 10µg/mL [peptido] and 1.75 mM [lipid] (1/500 molar ratio) -  method C 
► 10µg/mL [peptido] and 1.05 mM [lipid] (1/300 molar ratio) -  method C 
Samples were submitted to a previous amicon separation so that free peptide molecules could 
be excluded from analyses and the samples could be concentrated to boost the response by 
THP-1 cells. The intent was to increase peptide concentration as 10 µg/mL did not induce 
significantly high TNF-α concentrations (Figure 4.22) and detailed study about encapsulation 
of higher peptide concentrations had not been conducted. Therefore, the real peptide 
concentration came to be 23.8 µg/mL instead of 10 µg/mL and lipid concentration became to 
4.17 mM and 2.5 mM instead of 1.75 mM and 1.05 mM, respectively. 
Figure 4.23 presents TNF-α concentration produced by THP-1 cells after 4h of incubation 
with DODAC:MO (1:2) lipid vesicles (controls) and peptide/DODAC:MO(1:2) nanoparticles. 
The optical density (405 nm) was measured after 15 minutes of incubation with pNPP 
substrate and a calibration curve (Appendix III) was used to convert O.D. measures in TNF-α 
concentration (pg/mL). 
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Figure 4.23 – Quantitative results for TNF-α (pg/mL) produced by THP-1 cells in response to 
4h of incubation with DODAC:MO (1:2) vesicles and peptide/DODAC:MO(1:2) 
nanoparticles. Cells without any treatment, HEPES at 10 mM, LPS at 100% and peptide at 
23.8 µg/mL were used as controls. 
 
From Figure 4.23 we can observe that THP-1 cells naturally produced a small quantity of 
TNF-α, 1256 pg/mL, as expected. The production of this pro-inflammatory cytokine was 
higher when cells were incubated with HEPES buffer (10 mM), 1795 pg/mL. Peptide at a 
concentration of 23.8µg/ml was able to induce a higher response than cells and HEPES 
controls. LPS showed a very high production of a TNF-α concentration, 5205.5 pg/mL, as 
expected. 
Generally, lipid vesicles (controls) showed lower results when compared to peptide or HEPES 
samples, which means that the presence of lipid is not responsible for TNF-α overproduction.  
On one hand, vesicles produced by method C induced a slightly higher response at both molar 
ratios tested (1/300 and 1/500). On the other hand, vesicles prepared by method E induced an 
extremely strong response at only one peptide/lipid molar ratio (1/300). These findings 
support that liposomes as delivery vehicles are capable of increasing the index of a peptide or 
a drug as already reported in other studies (Gregory Gregoriadis, 2007a; Guan et al., 1998). 
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This will improve peptide biological effect and will allow decreasing the dose to be 
administrated. 
Despite having less lipid, 1/300 formulations showed a higher effect than 1/500 formulations. 
This indicates that the formulation that is capable of achieving the highest encapsulation 
efficiency is not necessarily the most effective in inducing an immune response. 
It is also important to refer that the data obtained from the ELISA reader showed gaps in some 
values (Appendix III). This is responsible for the result obtained for the lipid vesicles 
prepared by method C (control), with a total lipid content that correspond to the peptide/lipid 
1/300 molar ratio, as well as it may be disguising other results from Figure 4.23. 
Nevertheless, the lack of values for TNF-α production was observed for the smaller 
absorbance values, meaning for the samples that induced the weakest responses. 
Figures 4.24 and 4.25 show the most representative microscope images that focus the 
different outcomes of the distinct conditions. These pictures were taken using an inverted 
fluorescence microscope (Olympus IX71). 
 
Figure 4.24 – THP-1 cells after 4h, without any treatment (40x magnification). 
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Figure 4.25 – THP-1 cells after 4h of incubation with a peptide concentration of 100 µg/mL 
(40x magnification). 
 
Figure 4.24 shows that THP-1 cells have a cylindrical shape. Figure 4.25 shows that a peptide 
concentration of 100 µg/mL, after 4h of incubation, induced a change in very few cells. 
Nanoparticles produced a peculiar effect on THP-1 cells after 4h of incubation. This behavior 
was detected in all nanoparticles as well as in the respective controls. Several aggregates were 
visible at the naked eye at this time point of the experiment (images not shown). These 
peculiar outcomes may be due to a high lipid concentration as samples had to be concentrated 
prior to this analyzes in order to raise the probabilities of obtaining results with such a low 
peptide concentration. Nevertheless, there is no sign that this behavior is harmful to cells. 
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5. CHAPTER 5  CONCLUSIONS AND FUTURE DIRECTION 
5.1. Conclusions 
A neutral pH is a suitable condition to solubilize BCR-ABL peptide. Results suggested that 
acidic and alkaline conditions may induce changes in peptide’s secondary structure, possibly 
leading to its loss of function as well. 
In spite of citrate-phosphate buffer showed more desirable peptide features at acidic and 
alkaline conditions than HEPES buffer, HEPES was more adequate to produce nanoparticles 
at neutral conditions. 
DLS results (Zeta potential and mean diameter) showed that the nanoparticles produced 
depend on the protocol used and also on the peptide/lipid molar ratio. However, results 
suggested that the peptides were attached / incorporated into liposomes for all the different 
protocols. 
The four distinct protocols, as well as the four different peptide/lipid molar ratios, used in this 
study led to the production of different nanoparticles in terms of its conformational 
organization. The mean size and z-potential of the final nanoparticles are dependent or 
affected by lipid concentration, mode of preparation and peptide concentration. 
Increasing lipid concentration leads to a higher number of lipid vesicles, consequently 
decreasing the number of peptides per liposome and ultimately decreasing liposomes fusion. 
Results suggested that an increase in lipid concentration leads to an increasingly better 
peptide-liposome organization, but also that there is a critical concentration below which there 
is too much peptide that cannot be properly incorporated (1.05 mM). 
Lipid film hydration method produces more homogeneous nanoparticles than ethanolic 
injection.  
Nanoparticles prepared by post-insertion protocol leads to a higher peptide amount at the 
surface of vesicles when compared to direct-insertion technique. These peptides at the surface 
of liposomes induce membrane fusion, increasing nanoparticle´s mean size. 
The use of the extrusion process before or after peptide addition to liposomes preparation is a 
detrimental factor to achieve higher peptide encapsulation as this size-reducing process is 
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responsible for peptide loss. The distribution of intensity profiles showed that only at 1/500 
molar ratio formulation all the negative particles were neutralized when peptides were added 
after extrusion (method E).  
Lipid film hydration, method A, demonstrated higher encapsulation efficiency than ethanolic 
injection, method C. Higher lipid concentration showed higher peptide encapsulation, 
however, a lower lipid concentration was able to induce a stronger response by THP-1 cells.  
Gel electrophoresis technique using tricine was valuable to detect peptide presence/absence 
among the different samples, as well as to show that the methodology used to separate the free 
fraction from the encapsulated peptide fraction was successful. 
Peptide/DODAC:MO(1:2) nanoparticles were capable of inducing a stronger cells response 
than the peptide by itself. The most encouraging results were observed for 1/300 molar ratio 
(10 µg/mL of peptide concentration and 1.75 mM of lipid concentration) prepared by lipid 
film hydration and using the post-insertion protocol. 
The optimization of the control using LPS was successfully conducted and THP-1 cells 
worked as a suitable cell model. Nanoparticles produced a peculiar aggregation effect on 
THP-1 cells possibly due to a high lipid concentration. Cytotoxicity studies were not 
conducted; however, there is no morphological sign that this aggregation behavior is harmful 
to cells. In fact, based on previous studies, there are reasons to believe that this lipid content 
does not cause any harmful effect. 
Despite the cytotoxicity issues around cationic liposomes, it has been shown that they 
promote a much higher humoral and cytotoxic T lymphocyte immune response against the 
antigen (Chen & Huang, 2005).  
This thesis addressed the characterization of the cationic system DODAC/Monoolein (1:2) 
and emphasized its potential in the development of an immunoprotective treatment for 
chronic myeloid leukemia. 
After the preliminary results described in this thesis, encapsulation and delivery of the BCR-
ABL peptide can be optimized in future works.  
Potentiated biological activity of the system should be repeated for confirmation and ideally 
evaluated in in vivo models.  
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5.2. Future work 
In the next couple of years, consolidation therapy for myeloid leukemia will be more immune 
based. Antigen discovery associated to novel nanotechnology approaches will potentiate the 
development of vaccines targeting peptides that are highly specific to myeloid leukemia cells. 
Such discoveries will revolutionize survival perspectives of CML patients. 
Based on the preliminary results obtained in this study future developments can be made in 
the following research lines: 
● It would be valuable to test the incorporation of increasing peptide concentrations into 
DODAC:MO (1:2) lipid vesicles to elicit the most potent, yet highly leukemia-specific, 
immune responses. 
● Fluorescence anisotropy would be an excellent tool for the study of molecular interactions, 
since it provides important information about the location of the peptide within the liposome. 
Using fluorescently (e.g. FITC) labeled molecules would be helpful to quantify the 
incorporation of antigenic peptide. 
● It would be important to confirm the structural integrity of the peptides after their 
incorporation into liposomes. Circular Dichroism (CD) spectroscopy as one of the most 
sensitive methods for detecting changes in protein structure, would be useful to determine the 
structure of antigenic peptide when incorporated in the liposomal formulations  
● Other microscopic techniques to visualize particle’s features, as confocal fluorescence 
microscopy (CFM) using appropriate fluorophores, atomic force microscopy (AFM) or even 
scanning electron microscope (SEM), can represent powerful tools in this research field. 
● Imaging at high resolution is extremely useful both when characterizing biophysically the 
liposomes and when monitoring the uptake of nano-delivery systems by target cells. 
Incorporation of antigenic peptide and PEG-folate to be quantified by Confocal Raman 
microscopy (CRM) in order to obtain sub-micrometer resolved images of chemical 
components in the liposomes.  
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● With further understanding of the processes involved in immune response regarding CML, 
it will be possible to more accurately determine the optimal timing for the application of 
liposomal vaccine therapies to elicit the most potent immune responses. With exhaustive 
laboratory and animal data supporting leukemia liposomal vaccines, studies will be moving 
rapidly into the clinical setting. 
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Table 1 – Results of mean diameter (nm) of 10 µg/mL, 20 µg/mL and 40 µg/mL of BCR-
ABL peptide, in citrate-phosphate buffer at pH=4, 7.2 and 9, before and after sonication. 
pH Condition 
[peptide] 
(µg/m) 
Z-Ave 
(nm) 
PDI 
Pk 1  
(nm) 
Pk 2 
(nm) 
Pk 3 
(nm) 
Pk 1 
(%) 
Pk 2 
(%) 
Pk 3 
(%) 
Weighted 
Mean 
(nm) 
4 
before 
sonication 
10 2264,0 1,0 136,6 0,3 0,0 97,6 2,4 0,0 131,3 
20 1336,0 0,8 273,7 0,0 0,0 100,0 0,0 0,0 273,7 
40 1240,0 0,8 328,7 0,0 0,0 100,0 0,0 0,0 328,7 
after 
sonication 
10 3212,0 1,0 193,1 0,3 0,0 96,9 3,1 0,0 186,4 
20 979,4 0,7 331,4 0,0 0,0 100,0 0,0 0,0 331,4 
40 1406,0 0,8 480,9 0,2 0,0 97,6 2,4 0,0 470,9 
7,2 
before 
sonication 
10 848,8 0,8 256,1 0,3 0,0 98,3 1,7 0,0 251,3 
20 773,9 0,7 159,3 413,6 0,0 86,6 13,4 0,0 199,3 
40 507,0 0,6 268,0 0,0 0,0 100,0 0,0 0,0 268,0 
after 
sonication 
10 1110,0 0,8 229,5 0,0 0,0 100,0 0,0 0,0 229,5 
20 341,7 0,3 306,9 0,0 0,0 100,0 0,0 0,0 306,9 
40 699,2 0,6 299,1 17,2 0,0 98,1 1,9 0,0 294,1 
9 
before 
sonication 
10 1630,0 0,8 204,2 0,4 19,7 94,7 2,9 2,4 189,1 
20 1206,3 0,8 224,0 17,1 1853,3 87,9 11,3 0,8 244,3 
40 485,5 0,5 139,6 29,7 0,6 74,1 22,2 3,7 101,7 
after 
sonication 
10 382,4 0,4 59,9 12,3 0,0 87,4 12,6 0,0 53,7 
20 290,4 0,4 216,3 132,1 0,0 52,5 47,5 0,0 176,1 
40 402,5 0,4 159,2 23,5 0,0 95,6 4,4 0,0 153,2 
 
Table 2 – Results of mean diameter (nm) of 10 µg/mL, 20 µg/mL and 40 µg/mL of BCR-
ABL peptide, in citrate-phosphate (CP) and HEPES at pH=7.2, before and after sonication. 
Buffer Condition 
[peptide] 
(µg/mL) 
Z-Ave 
(nm) 
PDI 
Pk 1  
(nm) 
Pk 2 
(nm) 
Pk 3 
(nm) 
Pk 1 
(%) 
Pk 2 
(%) 
Pk 3 
(%) 
Weighted 
Mean 
(nm) 
 CP 
before 
sonication 
10,0 848,8 0,8 256,1 0,3 0,0 98,3 1,7 0,0 251,3 
20,0 773,9 0,7 159,3 413,6 0,0 86,6 13,4 0,0 199,3 
40,0 507,0 0,6 268,0 0,0 0,0 100,0 0,0 0,0 268,0 
after 
sonication 
10,0 1110,0 0,8 229,5 0,0 0,0 100,0 0,0 0,0 229,5 
20,0 341,7 0,3 306,9 0,0 0,0 100,0 0,0 0,0 306,9 
40,0 699,2 0,6 299,1 17,2 0,0 98,1 1,9 0,0 294,1 
HEPES 
before 
sonication 
10,0 598,9 0,6 544,0 93,7 0,0 87,8 12,2 0,0 489,0 
20,0 1275,0 0,9 390,5 37,6 1,0 80,4 13,9 5,7 317,0 
40,0 706,5 0,5 464,7 19,0 0,0 98,2 1,8 0,0 455,8 
after 
sonication 
10,0 656,5 0,6 486,4 90,1 0,0 90,8 9,2 0,0 450,1 
20,0 973,8 0,8 383,0 67,6 0,0 82,9 17,0 0,0 269,9 
40,0 916,2 0,6 858,0 131,0 1853,0 88,6 10,8 0,6 791,1 
  
 
 
 
 
 
 
 
 
 
 
 
 
(Page intentionally left blank) 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
APPENDIX II 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
(Page intentionally left blank) 
 
Development of a Liposomal Formulation for Peptide Delivery to Serve as Vaccine against CML Appendix II 
Fátima Machado   129 
 
Figure 1 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/100 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
  
Figure 2 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/200 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
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Figure 3 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/300 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
 
Figure 4 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method A and B at 1/500 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential.  
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Figure 5 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method C and D at 1/100 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
 
Figure 6 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method C and D at 1/200 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
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Figure 7 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬ - right axis) for peptide/DODAC:MO nanoparticles prepared by 
method C and D at 1/100 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
 
  
Figure 8 – At the left side are presented results of weighted mean size (nm) (bars - left axis) 
and z-potential (mV) (▬■▬- right axis) for peptide/DODAC:MO nanoparticles prepared by 
method C and D at 1/100 molar ratio, after extrusion. At the right side are presented the 
distribution of intensity profiles of the respective mean size and z-potential. 
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Figure 1 – Calibration curve for the optimization of the control LPS activation. 
 
Figure 2 – Calibration curve for peptide activation assay. 
 
Figure 3 – Calibration curve for peptide/DODAC:MO(1:2) formulations activation assay. 
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Table 1 – Results optical density (O.D.) and TNF-α concentration calculated from calibration 
curve obtained in an ELISA reader for different conditions tested in THP-1 cells after 15 
minutes of substrate incubation. 
Sample O.D. Outliers TNF-α (pg/mL) 
Cells 
0,079   Range? 
0,081   1255,98 
LPS 
0,419 Outlier 5209,637 
      
Peptide 
0,088   2006,068 
0,092   2234,897 
E 1.75mM 0,082   1465,187 
E 1.75mM 0,08   895,872 
E 1.75mM 0,093   2263,481 
E 1.75mM  0,079   Range? 
E 1.75mM (Control) 0,078   Range? 
E 1.75mM (Control) 0,074 Outlier Range? 
E 1.75mM (Control) 0,08   Range? 
E 1.75mM (Control) 0,081   1187,586 
E 1.05mM 0,078   Range? 
E 1.05mM 0,693 Outlier 7023,044 
E 1.05mM 0,077   Range? 
E 1.05mM 0,078   Range? 
E 1.05mM (Control) 0,078   Range? 
E 1.05mM (Control) 0,08   Range? 
E 1.05mM (Control) 0,071 Outlier Range? 
E 1.05mM (Control) 0,081   982,17 
C 1.75mM 0,099   2481,182 
C 1.75mM 0,084   1719,4 
C 1.75mM  0,083   1653,145 
C 1.75mM 0,079   Range? 
C 1.75mM (Control) 0,075 Outlier Range? 
C 1.75mM (Control) 0,086   1928,535 
C 1.75mM (Control) 0,079   Range? 
C 1.75mM (Control) 0,074 Outlier Range? 
C 1.05mM 0,087   1948,934 
C 1.05mM 0,211   3915,682 
C 1.05mM 0,08   895,872 
C 1.05mM 0,085   1804,633 
C 1.05mM (Control) 0,076   Range? 
C 1.05mM (Control) 0,073 Outlier Range? 
C 1.05mM (Control) 0,074 Outlier Range? 
C 1.05mM (Control) 0,079   Range? 
 
